176 results on '"E.J.T. Rutgers"'
Search Results
2. Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer
- Author
-
L.J. van 't Veer, E.J.T. Rutgers, Marc Schmidt, J.Lopes Cardozo, Fatima Cardoso, C. Poncet, and CA Drukker
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Prognostic factor ,medicine.medical_specialty ,business.industry ,Tumor biology ,medicine.medical_treatment ,Significant difference ,Gene signature ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Breast cancer ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Screening programs ,Treatment strategy ,business ,Adjuvant - Abstract
Studies have shown that screen detection by national screening programs is independently associated with better prognosis of breast cancer. The aim of this study is to evaluate the association between tumor biology according to the 70-gene signature (70-GS) and survival of patients with screen-detected and interval breast cancers. All Dutch breast cancer patients enrolled in the MINDACT trial (EORTC-10041/BIG3-04) accrued 2007–2011, who participated in the national screening program (biennial screening, ages 50–75) were included (n = 1102). Distant Metastasis-Free Interval (DMFI) was evaluated according to the 70-GS for patients with screen-detected (n = 754) and interval cancers (n = 348). Patients with screen-detected cancers had 8-year DMFI rates of 98.2% for 70-GS ultralow-, 94.6% for low-, and 93.8% for high-risk tumors (p = 0.4). For interval cancers, there was a significantly lower 8-year DMFI rate for patients with 70-GS high-risk tumors (85.2%) compared to low- (92.2%) and ultralow-risk tumors (97.4%, p = 0.0023). Among patients with 70-GS high-risk tumors, a significant difference in 8-year DMFI rate was observed between interval (85.2%, n = 166) versus screen-detected cancers (93.8%, n = 238; p = 0.002) with a HR of 2.3 (95%CI 1.2–4.4, p = 0.010) adjusted for clinical-pathological characteristics and adjuvant systemic treatment. Among patients with 70-GS high-risk tumors, a significant difference in DMFI was observed between screen-detected and interval cancers, suggesting that method of detection is an additional prognostic factor in this subgroup and should be taken into account when deciding on adjuvant treatment strategies.
- Published
- 2021
3. PH-0550 Importance of high thermal dose in post-operative re-irradiation and hyperthermia in breast cancer
- Author
-
H.S. Oldenburg, Arlene L. Oei, B.J. Slotman, H. P. Kok, M.W. Kolff, Hans Crezee, C.R.N. Rasch, E.J.T. Rutgers, A. Bakker, H.G.J.D. van den Bongard, G. van Tienhoven, I.R. Konings, and C. Tello Valverde
- Subjects
Hyperthermia ,Re-Irradiation ,Breast cancer ,Oncology ,business.industry ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,Post operative ,medicine.disease ,business ,Nuclear medicine ,Thermal dose - Published
- 2021
4. Abstract P6-13-01: MRI breast cancer screening compared to mammography in women with a familial risk: A multicenter randomized controlled trial
- Author
-
R.A.E.M. Tollenaar, H.J. de Koning, M van 't Riet, D. de Roy van Zuidewijn, H. M. Zonderland, Roger H. Mann, N. Karssemeijer, S. Saadatmand, I Mares-Engelbert, Cees Verhoef, I-M Obdeijn, M.M.A. Tilanus-Linthorst, M.J. Hooning, E.J.T. Rutgers, Jan C. Oosterwijk, Eveline A.M. Heijnsdijk, M.G.E.M. Ausems, Ernest J. T. Luiten, Marc B Lobbes, and Amarens Geuzinge
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Cancer ,medicine.disease ,law.invention ,Breast cancer ,Randomized controlled trial ,law ,Internal medicine ,Cancer screening ,medicine ,Mammography ,Family history ,Stage (cooking) ,business ,MRI breast - Abstract
Background: Screening guidelines for women with a family history of breast cancer without a known causative gene mutation differ per country. No randomized controlled trial has been performed to assess the optimal screening strategy for these women. Methods: In twelve centers, 1355 women aged 30–55 years with a cumulative lifetime risk of ≥20% without a BRCA1/2 mutation were randomized into two arms. From January 2011 until December 2017, women in the MRI-arm received yearly MRI-screening, clinical breast examination (CBE), and mammography every other year; and in the Mx-arm yearly mammography and CBE. Outcomes were number and stage of detected breast cancers, sensitivity, specificity and positive predictive value, and stratified by screening round and by mammographic density. Results: After on average 4.3 screening rounds per woman, in the MRI-arm (N=675) compared to the Mx-arm (N=680) more breast cancers were detected (41 versus 14, p Conclusions: In real-life practice the MRI-arm detected more, relevantly smaller, and far more often node negative tumors, and also at low density in women with a familial risk for breast cancer. Table 1Characteristics of participating women at baseline and of the detected breast cancers, according to study armParticipantsMRI-arm n=675Mx-arm n=680MRI-arm vs. Mx-arm p-valueMean age yr ± SD44.6 ± 6.244.7 ± 6.3 Premenopausal512 (76%)505 (74%) Previous Mx ≤ 2 yr536 (79 %)542 (80%) Previous Mx > 2 years ago23 ( 3%)29 ( 4%) Previous MRI ≤ 2 years ago62 ( 9%)81 (12%) Previous MRI > 2 years ago91 (14%)89 (13%) BI-RADS density category* I (entirely fat)88 (13%)92 (14%) II (scattered densities)248 (37%)229 (34%) III (heterogeneously dense)238 (35%)243 (36%) IV (extremely dense)98 (15%)102 (15%) Mean age at cancer detection49,6 ± 7.049,8 ± 4,70.74No cancer – no. (%)634 (94%)666 (98%) Invasive breast cancers – no. (%)25 (4%)7 (1%) Citation Format: Tilanus-Linthorst MM, Saadatmand S, Geuzinge AH, Rutgers EJ, Mann R, de Roy van Zuidewijn DB, Zonderland HM, Tollenaar RA, Lobbes MB, Ausems MG, van 't Riet M, Hooning MJ, Mares-Engelbert I, Luiten EJ, Heijnsdijk EA, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn I-M, de Koning HJ. MRI breast cancer screening compared to mammography in women with a familial risk: A multicenter randomized controlled trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-13-01.
- Published
- 2019
5. Outcome without any adjuvant systemic treatment in stage I ER+/HER2− breast cancer patients included in the MINDACT trial
- Author
-
J.Lopes Cardozo, Carolien H. Smorenburg, L.J. van 't Veer, C. Poncet, Danalyn Byng, E.J.T. Rutgers, Martine Piccart, Fatima Cardoso, CA Drukker, M.A. Binuya, Marc Schmidt, and Surgery
- Subjects
medicine.medical_specialty ,Receptor, ErbB-2 ,medicine.medical_treatment ,Estrogen receptor ,Breast Neoplasms ,Kaplan-Meier Estimate ,Gastroenterology ,Breast cancer ,Internal medicine ,Medicine ,Humans ,Cumulative incidence ,business.industry ,Proportional hazards model ,endocrine therapy ,Hazard ratio ,Endocrine therapy ,Hematology ,medicine.disease ,Combined Modality Therapy ,Treatment Outcome ,breast cancer recurrence ,Oncology ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,Propensity score matching ,low-risk breast cancer ,Female ,Neoplasm Recurrence, Local ,business ,Adjuvant ,no adjuvant systemic treatment - Abstract
Background: Adjuvant systemic treatments (AST) reduce mortality, but have associated short- and long-term toxicities. Careful selection of patients likely to benefit from AST is needed. We evaluated outcome of low-risk breast cancer patients of the EORTC 10041/BIG 3-04 MINDACT trial who received no AST. Patients and methods: Patients with estrogen receptor-positive, HER2-negative, lymph node-negative tumors ≤2 cm who received no AST were matched 1: 1 to patients with similar tumor characteristics treated with adjuvant endocrine therapy (ET), using propensity score matching and exact matching on age, genomic risk (70-gene signature) and grade. In a post hoc analysis, distant metastasis-free interval (DMFI) and overall survival (OS) were assessed by Kaplan–Meier analysis and hazard ratios (HR) by Cox regression. Cumulative incidences of locoregional recurrence (LRR) and contralateral breast cancer (CBC) were assessed with competing risk analyses. Results: At 8 years, DMFI rates were 94.8% [95% confidence interval (CI) 92.7% to 96.9%] in 509 patients receiving no AST, and 97.3% (95% CI 95.8% to 98.8%) in 509 matched patients who received only ET [absolute difference: 2.5%, HR 0.56 (95% CI 0.30-1.03)]. No statistically significant difference was seen in 8-year OS rates, 95.4% (95% CI 93.5% to 97.4%) in patients receiving no AST and 95.6% (95% CI 93.8% to 97.5%) in patients receiving only ET [absolute difference: 0.2%, HR 0.86 (95% CI 0.53-1.41)]. Cumulative incidence rates of LRR and CBC were 4.7% (95% CI 3.0% to 7.0%) and 4.6% (95% CI 2.9% to 6.9%) in patients receiving no AST versus 1.4% (95% CI 0.6% to 2.9%) and 1.5% (95% CI 0.6% to 3.1%) in patients receiving only ET. Conclusions: In patients with stage I low-risk breast cancer, the effect of ET on DMFI was limited, but overall significantly fewer breast cancer events were observed in patients who received ET, after the relatively short follow-up of 8 years. These benefits and side-effects of ET should be discussed with all patients, even those at a very low risk of distant metastasis.
- Published
- 2021
6. Abstract P1-07-02: Withdrawn
- Author
-
L van 't Veer, K Aalders, Konstantinos Tryfonidis, S. Delaloge, M.J. Piccart, Fatima Cardoso, A. Thompson, C. Poncet, Jan Bogaerts, E.J.T. Rutgers, and Isabel T. Rubio
- Subjects
Cancer Research ,Oncology - Abstract
This abstract was withdrawn by the authors.
- Published
- 2018
7. Abstract P1-07-08: Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial
- Author
-
Barbara Pistilli, T. van Dalen, Anne Kuijer, M.J. Piccart, E Genbrugge, Fatima Cardoso, K Aalders, C. Poncet, L van 't Veer, Konstantinos Tryfonidis, and E.J.T. Rutgers
- Subjects
Oncology ,Cancer Research ,Young age ,medicine.medical_specialty ,business.industry ,Internal medicine ,Medicine ,Disease ,Gene signature ,business - Abstract
Purpose: Increased insight in tumor biology has revealed that not all young women are at high risk of disease recurrence. Therefore, in some patients extent of treatment could probably be safely scaled down. We aimed to evaluate the risk of breast cancer (BC) relapse according to the 70-gene signature (70-GS) result in relation to young age, in early-stage BC patients enrolled in the MINDACT trial. Patients and Methods: The analyzed population consisted of enrolled BC patients in the MINDACT trial with available clinical (C), as per a modified version of Adjuvant!Online, and genomic (G), according to the 70-GS, risk assessments and known age (n=6693). Patients were categorized in three age groups; 55 years (post-menopausal). Clinicopathological and treatment characteristics as well as gene expression were compared for the different age groups further split by corrected risk groups (C-low/G-low, C-low/G-high, C-high/G-low, C-high/G-high). Subsequently, the 5-year distant metastasis-free survival according to risk category was calculated. Results: The study included 1100 patients 55 years of age (50%). Median age of the young group was 41 (25.8-45.0) years. The young age group had a higher frequency of lymph node involvement (25% vs. 22% and 19%), poorly differentiated tumors (42% vs. 26% and 27%), ER-negative tumors (20% vs. 11% and 11%) and triple negative molecular IHC subtype (16% vs. 9% ad 8%). Median tumor size was the same across the 3 age groups (17mm). Of the 1100 young patients, 61% were C-high while the 70-GS assessed 48% as G-high. Overall, 31% were CL/GL (vs. 43% in other age groups), 9% CL/GH, 21% CH/GL and 40% CH/GH (vs. 24% and 25%). In the discordant risk groups, chemotherapy (CT) allocation when randomized to no chemo occurred in 5% of young women as compared to 3% and 1% in the older age groups. Reason for non-compliance was 50/50 between patient refusal and PI decision. Overall, the 5-year DMFS was 94.1% (95% CI 92.4-95.4) in 55. For the young patients, 5-year DMFS was 98.3% for the CL/GL (96.0-99.3), 97.4% in CL/GH (90.0-99.4), 95.5% in CH/GL (91.6-97.7) and 89.2% in CH/GH (85.6-92.0). In the older two age groups (45-55 and >55), the 5-year DMFS rates were 97.8% (96.5.98.6) and 97.2% (96.2-98.0) for CL/GL, 93.9% (88.8-96.7) and 94.5% (91.0-96.7) for CL/GH, 94.5% (92.0-96.3) and 95.4% (93.5-96.8) for CH/GL and 92.0% (89.2-94.1) and 90.4% (88.0-92.4) for CH/GH, respectively. With 9 events in the Conclusion: The use of the 70-GS reduces the proportion of patients characterized as high risk as compared to traditional clinical risk assessment (48% vs. 61%). Outcome was comparable for the 3 age categories with a very good 5-year DMFS of 95-98% in all GL groups. Performing the 70-GS provides clinically relevant information concerning the prognosis for young early-stage BC patients categorized as CH. These results add important new data to the limited available evidence on genomic expression in young BC patients. Citation Format: Aalders K, Genbrugge E, Poncet C, Kuijer A, Pistilli B, Piccart M, Tryfonidis K, van Dalen T, Cardoso F, van 't Veer L, Rutgers E. Young age and the risk of disease recurrence as assessed by the 70-gene signature – an analysis from the EORTC 10041/BIG 03-04 MINDACT trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-08.
- Published
- 2018
8. Abstract P3-08-09: Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area
- Author
-
Carolien H. Smorenburg, Sabine Siesling, K. Schreuder, T. van Dalen, Anne Kuijer, and E.J.T. Rutgers
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Estrogen receptor ,Guideline ,medicine.disease ,Logistic regression ,Cancer registry ,Gene expression profiling ,Breast cancer ,Internal medicine ,medicine ,business ,Adjuvant - Abstract
Purpose In Dutch guidelines gene expression profiles (GEP) are indicated in estrogen receptor positive early breast cancer patients in whom benefit of chemotherapy (CT) is controversial based on traditional prognostic factors alone. Aim of the current study is to assess the use and impact of GEP on administration of adjuvant CT in breast cancer patients who have according to national guidelines a clear indication to either use or withhold adjuvant chemotherapy (clinical high or low risk). Methods Clinical low- and high risk patients, according to Dutch breast cancer guidelines, diagnosed between 2011-2014 were selected from the Netherlands Cancer Registry (NCR). Influence of GEP use and GEP test result on CT administration was assessed with logistic regression. Results Overall, 26,425 patients were identified; 4.8% of patients with clinical low- risk (444/ 9,354), 7.5% of the patients with a clinical high-risk (1,281/ 17,071) received a GEP. GEP use was associated with a significantly increased odds of CT administration in clinical low-risk patients (OR=2.12 95%CI: 1.44-3.11). In clinical high-risk patients GEP use was associated with a decreased frequency of CT administration (OR=0.55, 95%CI: 0.48-0.63). Adherence to the GEP result was higher in clinical high-risk patients with a discordant GEP result as compared to clinical low-risk patients with a discordant GEP result: 71.7% vs. 52.2%, respectively. Conclusion GEP is frequently used outside the indicated area and significantly influenced the administration of adjuvant CT, although adherence to the test-result was limited. Citation Format: Schreuder K, Kuijer A, Rutgers EJTh, Smorenburg CH, Van Dalen T, Siesling S. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-08-09.
- Published
- 2018
9. Abstract P3-12-08: Evaluation of treatment compliance during extended endocrine therapy; secondary analysis of the IDEAL trial
- Author
-
J.W.R. Nortier, Judith R. Kroep, Cjh van de Velde, E.J.T. Rutgers, E.J. Blok, M. Duijm-de Carpentier, and E. Meershoek-Klein Kranenbarg
- Subjects
Cancer Research ,medicine.medical_specialty ,Randomization ,business.industry ,Letrozole ,medicine.disease ,Discontinuation ,Clinical trial ,Breast cancer ,Oncology ,Internal medicine ,medicine ,Adjuvant therapy ,Adverse effect ,business ,Depression (differential diagnoses) ,medicine.drug - Abstract
In the first clinical trial reports about extended endocrine therapy in early breast cancer, treatment compliance appeared as a major concern. Earlier, it was shown in the IDEAL trial that approximately 35% of all patients stopped therapy before the allocated time. This additional study was conducted to evaluate the factors contributing to early treatment discontinuation. Methods: In the IDEAL trial, a total of 1824 patients were randomized between either 2.5 or 5 years of extended letrozole, after 5 years of any adjuvant endocrine therapy. Only eligible patients who started therapy were included in the analysis. Adverse events were collected until 30 days after last treatment dose Reasons for ending therapy were collected prospectively at the time of treatment discontinuation. Results: The majority of early treatment discontinuation was caused by adverse events (AEs) (n=372, 20.4% of all patients, 58% of all early treatment discontinuations). The most frequently reported AEs associated to treatment discontinuation were arthralgia (n=71, 9.9% of AEs associated treatment discontinuation), fatigue (n=48, 6.7%), depression (n=47, 6.5%), hot flashes (n=47, 6.5%) and alopecia (n=39, 5.4%). Of all AEs associated to early discontinuation, 86% was grade 1 or 2 (table 1). All grade 5 events were not associated to therapy. Table 1 - Overview of adverse events most frequently associated to early treatment discontinuation Grade 1Grade 2Grade 3Grade 4Grade 5TotalArthralgia2236121071Fatigue192610148Depression202160047Hot flashes162092047Alopecia28731039Total (all AEs)30231680136720 Furthermore, the influence of previous type of adjuvant endocrine therapy was evaluated. Of all patients initiallytreated with 5 years of tamoxifen, 29% stopped due to an AE. In contrast, patients who were treated with aromatase inhibitors during the first 5 years, either with monotherapy or after 2-3 years of tamoxifen, stopped due to AEs in 22% and 18% respectively (Pearson Chi-square p-value 0.001). The average number of AEs per patient per previous treatment group was 2.27 for tamoxifen monotherapy, 2.03 for AI monotherapy and 1.73 in the sequential group. Corrected for the number of AEs in each group, patients pre-treated with 5 years of tamoxifen had a chance of treatment discontinuation of 12.7% per AE, compared to 10.8% and 10.4% for AI monotherapy and sequential therapy respectively. Additionally, of patients that completed regular adjuvant therapy between 1 and 2 years before randomization, 34% stopped due to adverse events. In contrast, of patients that completed therapy within 6 months before randomization stopped in 19% of all cases (Pearson Chi-square p-value Conclusion: We have shown that adverse events are an important factor in early treatment discontinuation. Furthermore, the relation between adverse events and early discontinuation is influenced by the type of earlier therapy, with the highest rate of discontinuation for AI-naïve patients. This suggests that after 5 years of tamoxifen, patients are more inclined to stop therapy when encountering new AI-related adverse events compared to patients who were pre-treated with an AI. Citation Format: Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Nortier JWR, Rutgers EJTh, van de Velde CJH. Evaluation of treatment compliance during extended endocrine therapy; secondary analysis of the IDEAL trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-12-08.
- Published
- 2018
10. Abstract P4-12-01: MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer
- Author
-
C. Poncet, F Cardoso, Valesca P. Retèl, E.J.T. Rutgers, MA Joore, L.J. van 't Veer, K Tryfonidis, W.H. van Harten, and MJ Piccart
- Subjects
Oncology ,Cancer Research ,education.field_of_study ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Total cost ,Population ,Cancer ,medicine.disease ,Quality-adjusted life year ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,MammaPrint ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,030212 general & internal medicine ,Stage (cooking) ,business ,education ,health care economics and organizations ,Reimbursement - Abstract
Rationale: The 70-gene signature (MammaPrint®, MP) is a prognostic test which guides treatment decisions in patients with early breast cancer. After level 1A evidence for clinical utility of MP has been proven, cost-effectiveness data is important to inform reimbursement. Research objectives: To compare cost-effectiveness of adding MP to clinical risk assessment versus clinical risk assessment alone for the US and EU. Clinical risk was assessed by Adjuvant Online! (AOL) as described in Cardoso et al. NEJM 2016. We used prospective survival data from the large randomized phase 3 trial 'Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy' (MINDACT). Methods: We used a Markov decision model to estimate the expected costs and outcomes (quality adjusted life years; QALYs) for MP versus AOL in early breast cancer patients from a payers perspective in the US and a societal perspective in the EU over a 5 year time horizon. Five year breast cancer overall- and distant metastasis free survival was calculated based on the MINDACT population (n=6,693). Utility scores were collected by means of the EuroQol-5D in the pilot phase of MINDACT(the first n=800 MINDACT patients). Cost data were for the US based on published insurance claim data, for the EU on published health care- and societal costs. The cost-effectiveness was calculated for: (1) total early stage breast cancer population, (2) clinical high risk population and (3) clinical high risk group in the ER+/HER2- population. Finally, budget impact for a high-low range of different countries was calculated, as the application and costs of chemotherapy can be highly variable between countries. Results: For all groups (1,2,and 3) in the US, using MINDACT survival data and insurance claim data, adding MP to AOL saved costs and gained more QALYs compared to AOL alone (total costs per patient $42,223 vs $45,566 and 4.035 vs 4.031 QALYs respectively). Thus, a small difference in quality adjusted life years (0,0041) was observed, whereas a large difference in costs ($3,342) renders MP a highly cost-effective test (less costly & more effective in 64% of the cases). The largest cost-benefit effect was seen for group 3. The cut-off point for MP being cost-effective in the total population (group 1) is when the chemotherapy costs (and consequences) together are above $30,000. In the US, with approximately 250,000 new breast cancer patients per year, and a cost saving of $3,342, annual budget savings are expected to be $836M. Similar results for the Netherlands (15,000 breast cancer patients per year), reveal a cost difference of $300 per patient, and overall annual budget savings are expected to be $4,5M. Conclusion: Adding MP to clinical risk assessment is highly cost-effective compared to clinical risk assessment alone, based on the MINDACT survival data and US insurance claim data, for all above mentioned groups. When costs for chemotherapy (and consequences) exceed $30,000, MP is cost-effective for the total early breast cancer population. When costs for chemotherapy (and consequences) are below $30,000, the MP is cost-effective for the clinical high risk early breast cancer group. The separate results for EU countries will follow. Citation Format: Retèl VP, Joore MA, van 't Veer LJ, Cardoso F, Piccart MJ, Rutgers EJ, Tryfonidis K, Poncet C, van Harten WH. MammaPrint is cost-effective compared to clinical risk assessment in early stage breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-12-01.
- Published
- 2018
11. Abstract OT3-07-01: Update of the randomized, non-inferiority LORD trial testing safety of active surveillance for women with screen-detected low risk ductal carcinoma in situ (EORTC-1401-BCG/BOOG 2014-04, DCIS)
- Author
-
K Aalders, Victoria P Skinner, C. Loo, Jelle Wesseling, C. Poncet, Ruud M. Pijnappel, Valesca P. Retèl, E van Leeuwen-Stok, Gonneke A. O. Winter-Warnars, Konstantinos Tryfonidis, Lotte E. Elshof, F. van Duijnhoven, N. Bijker, E.J.T. Rutgers, and Eveline M. A. Bleiker
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Standard treatment ,Population ,Cancer ,medicine.disease ,03 medical and health sciences ,Breast cancer screening ,0302 clinical medicine ,Breast cancer ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Hormonal therapy ,030211 gastroenterology & hepatology ,Overdiagnosis ,education ,business ,Mastectomy - Abstract
The introduction of population-based breast cancer screening and implementation of digital mammography have led to an increased incidence of ductal carcinoma in situ (DCIS) without a decrease in the incidence of advanced breast cancer. This suggests DCIS overdiagnosis exists. We hypothesize that asymptomatic, low-grade DCIS can safely be managed by active surveillance. If progression to invasive breast cancer would still occur, this will be low-grade and hormone receptor positive with excellent survival rates. Also, breast-conserving treatment will still be an option, if no prior radiotherapy has been applied. Management by active surveillance also may save many low-grade DCIS patients intensive treatment. Therefore, we will compare active surveillance with conventional treatment, being either mastectomy, wide local excision (WLE) only, or WLE plus radiotherapy, possibly followed by hormonal therapy for primary low-grade DCIS. For this, we conduct a phase III, open-label, non-inferiority, multi-center, randomized clinical trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC-1401-BCG). The Dutch Centers are coordinated by the Dutch Breast Cancer Research Group (BOOG) (BOOG 2014-04). This trial is developed and implemented in close collaboration with patient advocates. Randomization will be in a 1:1 ratio among one of the following arms: (1) active surveillance or (2) standard treatment per local policy. In total, 1,240 women (≥ 45 years) will be included without prior breast cancer, but with asymptomatic, pure, low-grade DCIS, based on a minimum of tissue harvested by biopsy from calcifications detected by population-based or opportunistic screening. Assuming 25% of randomized women qualified to enroll in the study will drop out or will be excluded from per protocol evaluation, at least 1,240 women need to be randomized to obtain the 930 patients required for the evaluation of the primary endpoint. The same follow-up scheme will be applied in both study arms, i.e. annual mammography for a period of 10 years. The primary end-point is ipsilateral invasive breast tumor-free rate at 10 years. Secondary end-points are among others: overall survival, breast cancer-specific survival, mastectomy rate, patient reported outcomes and cost-effectiveness. Accrual has started in the Netherlands in February 2017 and will start internationally in over 30 centers shortly. Acknowledgements: This trial is funded by Pink Ribbon Netherlands, the Dutch Cancer Society and Dutch Cancer Society/Alpe d'HuZes, and Cancer Research UK. Citation Format: Wesseling J, Elshof LE, Tryfonidis K, Poncet C, Aalders K, van Leeuwen-Stok E, Skinner V, Loo C, Winter-Warnars G, Bleiker E, Retèl V, Pijnappel R, Bijker N, Rutgers E, van Duijnhoven F. Update of the randomized, non-inferiority LORD trial testing safety of active surveillance for women with screen-detected low risk ductal carcinoma in situ (EORTC-1401-BCG/BOOG 2014-04, DCIS) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-07-01.
- Published
- 2018
12. PET/CT with 18 F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease
- Author
-
Marcel P. M. Stokkel, Vincent van der Noort, Suzana C Teixeira, Bas B. Koolen, M.T.F.D. Vrancken Peeters, Sjoerd Rodenhuis, E.J.T. Rutgers, R.A. Valdés Olmos, P. Elkhuizen, and Other departments
- Subjects
PET-CT ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,General Medicine ,Stage ii ,medicine.disease ,Occult ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,medicine ,Surgery ,030212 general & internal medicine ,Radiology ,Lymph ,Stage (cooking) ,Nuclear medicine ,business ,Lymph node - Abstract
Introduction: F-18-FDG PET/CT has high positive predictive value for the detection of avid lymph node metastases in breast cancer patients. We analysed the effect of upstaging lymph nodes by PET/CT on short-term outcome in stage II/III breast cancer patients. Patients and methods: A total of 278 stage II/III primary breast cancer patients (mean age 48.9 years, range 19-75 years) were re-staged with 18F-FDG PET/CT before start of pre-operative systemic treatment (PST). Patients were divided in three groups based on risk for local recurrence: a low - (T2N0), intermediate - (T0-2N1 and T3NO) and a high-risk group (T0-3N2-3, T3N1 and T4). Within these groups we looked at local recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) within the first 3 years of followup. Results: With a median follow-up (FU) of 50 months the RFS, LRFS and OS were 87%, 88% and 92% respectively for the whole group. PET/CT upstaged 43 patients from the low- and intermediate risk group to the high-risk group, based on detection of >= 4 avid axillary nodes or occult N2/3-disease. Patients upstaged with PET/CT had more events for all three analyses compared to the original risk groups, which resulted in a significantly worse RFS (69.8%; p = 0.03) a nearly significantly worse LRFS (p = 0.052) and no effect in OS (p = 0.433). Discussion: Additional PET/CT staging allows breast cancer patients to be treated according to the true stage, still stage II/III breast cancer patients upstaged to N2/3 by PET/CT have worse short-term outcome, despite adjustment of treatment, than patients staged high-risk with conventional imaging. (C) 2016 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved
- Published
- 2017
13. Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)
- Author
-
HM Oosterkamp, Jelle Wesseling, E. van Werkhoven, Marleen Kok, Iam Mandjes, E.J.T. Rutgers, Agh van Rossum, A.L.T. Imholz, Sabine C. Linn, Mark Opdam, Jea Portielje, A. van Bochove, E van Leeuwen-Stok, Sjoerd Rodenhuis, H. van Tinteren, and Mmem Bos
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Doxorubicin/Cyclophosphamide ,medicine.disease ,Breast cancer ,Docetaxel ,Internal medicine ,medicine ,business ,Adjuvant ,medicine.drug - Abstract
Background: Anthracycline-based adjuvant chemotherapy has substantially improved breast cancer survival. Both the addition of taxanes as well as using a dose dense treatment schedule can further ameliorate outcome, but inter-individual differences exist. Here we present the efficacy and toxicity of dose dense scheduled doxorubicin/cyclophosphamide (ddAC) versus docetaxel/doxorubicin/cyclophosphamide (TAC), which is, to our knowledge, the first direct comparison of these treatment regimens. Methods: In this Dutch, multicenter phase III trial (ISRCTN61893718), patients with pT1-3, pN0-3, M0 breast cancer were randomized between six cycles of either A60C600 every 2 weeks or T75A50C500 every 3 weeks. All patients received pegfilgrastim. Patients were evaluated for recurrence-free survival (RFS) and overall survival (OS). Survival was compared in a Cox regression analysis and adjusted for known prognostic factors. These factors include age, type of surgery, tumor size, histological grade, ER/PR status, HER2 status, and lymph node status. Adverse events were reported according to the common toxicity criteria (CTCAE version 3.0). Results: Between 2004 and 2012, 664 patients were enrolled of whom 531 (80%) had node positive disease. At a median follow up of 5 years, OS was 92% in the ddAC treated subgroup and 93% in the TAC treated subgroup (adjusted hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.42-1.34, intention to treat population). Forty-two breast-cancer specific deaths were equally divided over both treatment arms. Similarly, no significant difference in RFS was observed between both treatment groups (adjusted HR 0.85, 95% CI 0.55-1.32). Molecular subtypes were defined by St. Gallen criteria: 548 patients (83%) had estrogen receptor positive disease and 102 patients (15%) triple negative disease. No heterogeneity regarding treatment efficacy was observed in these subtypes. In particular, there was no survival benefit for ddAC or TAC in the triple negative subtype. Both treatment regimens were well tolerated. Whereas anemia was more frequent in ddAC treated patients (19% vs 4.7%; p Conclusions: At a median follow up of 5 years no significant survival differences were observed between adjuvant ddAC and TAC, in all patients and in molecular subgroups, including triple negative. Our findings are in line with the Oxford overview, which reported no significant differences between taxane-based chemotherapy and more, non-taxane based chemotherapy given in a dose dense schedule. ddAC could be a reasonable alternative for patients with a contra-indication for TAC. Citation Format: van Rossum AGH, Oosterkamp HM, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok E, van Tinteren H, Kok M, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Rodenhuis S, Linn SC. Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-14-03.
- Published
- 2017
14. Abstract P6-09-03: Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study
- Author
-
Carolien H. Smorenburg, Jelle Wesseling, E.J.T. Rutgers, Sabine C. Linn, M.E. Straver, S. G. Elias, Sabine Siesling, T. van Dalen, and Anne Kuijer
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Adjuvant chemotherapy ,business.industry ,030503 health policy & services ,Gene signature ,03 medical and health sciences ,Internal medicine ,medicine ,Symphony ,0305 other medical science ,business ,Early breast cancer - Abstract
PURPOSE: gene-expression profiles, such as the 70-gene signature (70-GS), are increasingly used as adjunct to conventional clinicopathological prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in estrogen-receptor (ER) positive (+) early stage breast cancer patients without overt lymph node metastases. We aimed to assess the impact of the 70-GS on CT decisions in ER+ early stage breast cancer patients. PATIENTS AND METHODS: In this prospective observational multicenter study physicians were asked for their opinion whether to administer or omit adjuvant CT before deployment and after obtaining the test result of the 70-GS in this guideline delineated group of patients. RESULTS: Between January 1 2013 And December 31 2015 660 patients, treated in 31 hospitals, were enrolled. Based on the clinicopathological postoperative findings physicians would administer CT in 41%, withhold CT in 16% of patients and refrained from formulating an advice in the remaining 43% of patients letting their recommendation depend on the result of the 70-GS. Estimated 5-year survival benefit of CT administration was 0.8%, 0.6% and 0.7% respectively (p 0,585). The 70-GS result hardly varied in relation to the initial advice of the physician: 56% and 59% had a low-risk profile in patients in whom CT was recommended or discommended respectively (r =0.021, Table 1). In 51% of patients in whom a pre-test recommendation was formulated incorporation of the 70-GS test result changed the initial advice. Adherence to the test result was high for the three groups (range 94-97%). Table 1. Concordance between pre-test CT recommendation of the oncologist and the 70-gene signature (GS) test result. 70-GS test resultPre-test CT recommendationno. patientsLow RiskHigh RiskNo CT10763 (59%)44 (41%)CT270152 (56%)118 (44%)Depends on 70-GS result283174 (61%)109 (39%)Note. Agreement between pre-test oncologist CT recommendation and the 70-GS test result: Pearsons r = -0,031 95%CI (-0,11 – 0,045). Table 2. CT recommendation before vs. after obtaining the 70-GS test result and the actual administration of CT. Post-test CT recommendationAdherence to test result*Actual administered CTAdherence to test result*Pre-test CT recommendationno. patientsNo CTCT%No CTCT%No CT10769 (65%)38 (35%)94%73 (68%)34 (32%)91%CT207156 (58%)114 (42%)97%162 (60%)108 (40%)90%Depends on 70-GS result283173 (61%)110 (39%)95%185 (65%)98 (35%)91%*Percentage of patients in whom the post-test recommendation/actual administered CT was in line with the 70-GS test result (i.e. no CT in case of a low-risk profile and CT in case of a high-risk profile. Note. Change in CT recommendation in patients with a CT or no CT pre-test recommendation McNemar's chi-square test p < 0.001 and p < 0.001 for actual administered CT CONCLUSION: guideline-directed use of the 70-GS in Dutch ER+ early breast cancer patients influenced CT treatment decision in the majority of patients. The physician's tentative CT advice was not associated with the 70-GS test-result. Citation Format: Kuijer A, Straver M, Elias S, Smorenburg C, Wesseling J, Linn S, Rutgers E, Siesling S, van Dalen T. Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-03.
- Published
- 2017
15. FaMRIsc trial shows: MRI breast screening for women with ≥20% lifetime risk is also cost-effective in Europe
- Author
-
Ernest J. T. Luiten, Amarens Geuzinge, Eveline A.M. Heijnsdijk, S. Saadatmand, Madeleine M.A. Tilanus-Linthorst, Maartje J. Hooning, M. van 't Riet, Jelle Wesseling, R.A.E.M. Tollenaar, E.J.T. Rutgers, H.J. de Koning, S.V. Margrethe, D. de Roy van Zuidewijn, Cees Verhoef, Roger H. Mann, Jan C. Oosterwijk, Inge-Marie Obdeijn, Margreet G. E. M. Ausems, and K. Kristine
- Subjects
medicine.medical_specialty ,Oncology ,Obstetrics ,business.industry ,medicine ,Surgery ,Lifetime risk ,General Medicine ,business ,MRI breast - Published
- 2021
16. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
- Author
-
Luc J. A. Strobbe, L.M. van Roozendaal, E.J.T. Rutgers, M. Klinkert, B. Goorts, B. de Vries, Y. E. A. van Riet, Jelle Wesseling, Marjolein L. Smidt, C. A. P. Wauters, E. Degreef, Kristien Keymeulen, Promovendi ODB, Beeldvorming, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Heelkunde (9), Surgery, and Pathologie
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,DCIS ,medicine.medical_treatment ,Sentinel lymph node ,Breast Neoplasms ,030230 surgery ,Mastectomy, Segmental ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Breast cancer ,Sentinel lymph node biopsy ,Risk Factors ,Biopsy ,medicine ,Breast-conserving surgery ,Humans ,Neoplasm Invasiveness ,Fisher's exact test ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Incidence ,Middle Aged ,Ductal carcinoma ,medicine.disease ,Clinical Trial ,Surgery ,Treatment ,Carcinoma, Intraductal, Noninfiltrating ,Oncology ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,symbols ,Female ,Histopathology ,Sentinel Lymph Node ,business ,Mastectomy - Abstract
Breast cancer guidelines advise sentinel lymph node biopsy (SLNB) in patients with ductal carcinoma in situ (DCIS) on core biopsy at high risk of invasive cancer or in case of mastectomy. This study investigates the incidence of SLNB and SLN metastases and the relevance of indications in guidelines and literature to perform SLNB in order to validate whether SLNB is justified in patients with DCIS on core biopsy in current era. Clinically node negative patients diagnosed from 2004 to 2013 with only DCIS on core needle biopsy were selected from a national database. Incidence of SLN biopsy and metastases was calculated. With Fisher exact tests correlation between SLNB indications and actual presence of SLN metastases was studied. Further, underestimation rate for invasive cancer and correlation with SLN metastases was analysed. 910 patients were included. SLNB was performed in 471 patients (51.8 %): 94.5 % had pN0, 3.0 % pN1mi and 2.5 % pN1. Patients undergoing mastectomy had 7 % SLN metastases versus 3.5 % for breast conserving surgery (BCS) (p = 0.107). The only factors correlating to SLN metastases were smaller core needle size (p = 0.01) and invasive cancer (p
- Published
- 2016
17. Abstract P5-17-06: Prognostic value of method of detection in primary pure DCIS
- Author
-
Marc Schmidt, E.J.T. Rutgers, Jelle Wesseling, Lotte E. Elshof, F.E. van Leeuwen, and Michael Schaapveld
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,Oncology ,business.industry ,Medicine ,Radiology ,business ,Value (mathematics) - Abstract
Background Population-based mammographic screening programs have led to a substantial increase in incidence of ductal carcinoma in situ (DCIS). We assessed whether the method of detection provides prognostic information among women with DCIS detected through the Dutch screening program (screen-detected DCIS) and those with DCIS not detected within the national screening program (non-screen-detected DCIS). This could have impact on the treatment strategy of screen-detected DCIS as compared to symptomatic DCIS. Methods We studied a population-based retrospective cohort comprising 7,106 women aged 49-76 years with primary pure DCIS, who were treated by mastectomy or breast conserving surgery with or without radiotherapy between 1989 and 2004 in the Netherlands. Risk of subsequent ipsilateral and contralateral invasive breast cancer and overall survival among women with screen-detected (n=4,905) and non-screen-detected (n=2,201) DCIS were compared using Cox regression, adjusting for treatment (time-dependent), age (time-scale), diagnosis period and follow-up duration. Because of gradual implementation of the screening program in the Netherlands, we defined two periods based on year of DCIS diagnosis: 1989-1998 (gradual implementation of screening) and 1999-2004 (full coverage of screening). Results With a median follow-up of 10.5 years (interquartile range 7.7-14.0 years) 366 ipsilateral (screen-detected DCIS n=234, non-screen-detected DCIS n=132) and 380 contralateral (screen-detected DCIS n=245, non-screen-detected DCIS n=135) invasive breast cancers were diagnosed, and 1,088 of 7,106 women died (screen-detected DCIS n=603, non-screen-detected DCIS n=485). From 1989 to 2004 the number of non-screen-detected DCIS remained stable (mean 140, range 110-187 per year), whereas the number of screen-detected primary pure DCIS increased from 8 in 1989 to 596 in 2004. Ipsilateral invasive breast cancer risk was lower for screen-detected DCIS compared to DCIS not detected within the national screening program, irrespective of DCIS treatment, period of diagnosis, and follow-up duration (adjusted hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.59-0.92, p < 0.01). The prognostic value of method of detection was similar across categories of treatment, period of diagnosis, and follow-up duration. The risk of contralateral invasive breast cancer did not differ between screen-detected DCIS and non-screen-detected DCIS (adjusted HR 0.89, 95% CI 0.71-1.11, p = 0.3) and neither did all-cause mortality (adjusted HR 0.91, 95% CI 0.79-1.04, p = 0.2). Conclusion Women with primary pure DCIS detected through the Dutch screening program had lower risk of subsequent ipsilateral invasive breast cancer, irrespective of DCIS treatment, compared to women whose DCIS was not detected within the national screening program. However, the magnitude of this risk difference does not warrant a different treatment strategy of screen-detected DCIS as compared to non-screen-detected DCIS. Having a screen-detected DCIS was not associated with risk of subsequent contralateral invasive breast cancer and all-cause mortality. Citation Format: Elshof LE, Schaapveld M, Schmidt MK, van Leeuwen FE, Rutgers EJTh, Wesseling J. Prognostic value of method of detection in primary pure DCIS. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-17-06.
- Published
- 2016
18. Abstract P5-17-09: Biomarkers to distinguish hazardous from harmless ductal carcinoma in situ (DCIS) of the breast
- Author
-
K.K. Van de Vijver, Frank Nieboer, Lotte E. Elshof, Emma J. Groen, Lindy L. Visser, E.J.T. Rutgers, M de Maaker, Michael Schaapveld, Jelle Wesseling, and Esther H. Lips
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,education.field_of_study ,business.industry ,medicine.medical_treatment ,Population ,Ductal carcinoma ,medicine.disease ,Radiation therapy ,Breast cancer ,Oncology ,Ductal carcinoma in situ (DCIS) ,Breast-conserving surgery ,medicine ,Population study ,Overdiagnosis ,skin and connective tissue diseases ,business ,education - Abstract
Background. The incidence of DCIS has increased since the introduction of population-based screening. This has not resulted in a decrease in invasive breast cancer incidence, implying overdiagnosis exists. All women with DCIS are still intensively treated, by surgery, radiotherapy, and/or hormonal treatment, although only a minority will develop a subsequent invasive breast cancer. As we cannot discriminate such hazardous from harmless DCIS lesions, accurate prognostic biomarkers are urgently needed. In the current study we aim to identify molecular markers for DCIS aggressiveness, using a large population-based cohort. Patients and methods. We used a population-based, nation-wide cohort consisting of 10,090 women treated for primary DCIS between 1989 and 2004 with a median follow-up time of 10.7 years. Within this cohort, a case-control study was set up to analyse which markers are associated with progression to invasive breast cancer. Formalin-fixed paraffin embedded (FFPE) tissue blocks were retrieved from 1580 DCIS patients who were treated by breast conserving surgery without radiotherapy (316 DCIS patients with a subsequent ipsilateral invasive breast cancer (iiBC): i.e. the "cases"; and 1264 DCIS patients without subsequent invasive breast cancer: i.e. the "controls"). A first study using this population-based cohort will involve immunohistochemistry (IHC) on 200 "cases" and 500 "controls" for an 8-marker IHC panel (ER, PR, HER2, Ki67, p16, p53, COX-2, and Annexin A1). Molecular subtypes of the DCIS and invasive breast cancer lesions will be determined and intra-individual heterogeneity will be assessed. IHC marker expression will be both compared between "cases" and " controls" as well as between DCIS lesions and its subsequent invasive breast cancer. In a second study, DNA and RNA will be isolated from these specimens, using laser microdissection, and extensive molecular profiling will be performed. Results. We have collected FFPE tissue blocks of 287 "cases" and 1149 "controls" (86% of requested material) from 56 participating hospitals. At present, the specimens of 223 "cases" (matched DCIS and iiBC specimen) and 103 "controls" have been centrally revised for extensive morphological characteristics. Only a small part (14%) of the specimens had to be excluded from the study population. IHC staining of the tissue specimens, using the 8-marker IHC panel is ongoing. Conclusion. Within a nation-wide cohort of 10,090 patients diagnosed with primary DCIS, we were able to collect tissue material of a representative case-control series of 200 "cases" with subsequent invasive breast cancer and 500 invasive breast cancer-free "controls". This is the first time such a large unique, unbiased DCIS series, with long-term follow-up is analysed integrating clinical, histological, and immunohistochemical data. The results will be presented at SABCS 2015. Citation Format: Visser L, Elshof L, Groen E, van de Vijver K, Lips E, de Maaker M, Nieboer F, Schaapveld M, Rutgers E, Wesseling J. Biomarkers to distinguish hazardous from harmless ductal carcinoma in situ (DCIS) of the breast. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-17-09.
- Published
- 2016
19. Abstract P1-03-04: Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study
- Author
-
M.E. Straver, E.J.T. Rutgers, T. van Dalen, Anne Kuijer, Carolien H. Smorenburg, Sabine Siesling, Sabine C. Linn, Jelle Wesseling, and S. G. Elias
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Oncology ,Microarray ,business.industry ,Concordance ,medicine ,Symphony ,Immunohistochemistry ,business ,Subtyping - Abstract
PURPOSE: A decade ago intrinsic biological breast cancer subtypes have been identified which have proven to be of clinical importance in terms of outcome and response to systemic treatment. The aim of the current study is to assess concordance between breast cancer subtypes determined by local immunohistochemistry (IHC) assessment of estrogen receptor (ER), progesterone receptor (PR) and Her2-receptor status and microarray based molecular subtyping in a subset of ER+ early stage breast cancer patients. PATIENTS AND METHODS: In this prospective observational multicenter study information on local pathology assessment and BluePrint/TargetPrint results were obtained in ER+ Dutch early stage breast cancer patients in whom a 70-gene profile (MammaPrint) was used as they were enrolled in clinical trial based on the existence of controversy regarding the additional value of adjuvant CT. Local IHC assessment of ER, PR and Her2 status were compared with microarray based assessment (TargetPrint/BluePrint) of these characteristics. Reclassification of ER and PR overexpression was assessed by a McNemars test and by Spearman correlation. Furthermore, concordance between the clinical subtypes based on local pathology (Luminal-type: ER+/PR+/Her2-; Her2-type: Her2+ disease) and molecular subtyping was assessed. RESULTS: Between January 2013 And December 2015 660 patients, treated in 31 hospitals, were enrolled. In 564 (85%) BluePrint and/or TargetPrint was performed in addition to the 70-GS. The majority of patients had ER+/Her2- disease and TargetPrint reclassified 1% (n = 7) of patients as ER-negative (r = 0,250, p Table 1. Concordance between immunohistochemistry and TargetPrint. TargetPrint result (ER, PR and Her2 resp.) ImmunohistochemistryPositiveNegativeOverall discordance (%)p-value*Estrogenreceptor status Positive557 (99%)6 (1%) Negativen.a.n.a.1%n.a.Progesterone receptor status Positive474 (96%)18 (4%) Negative22 (31%)49 (69%)7%0,636Her2 receptor status Positive3 (30%)7 (70%) Negative4 (3%)546 (97%)2%0,549Equivocal0 (0%)3 (1%) * P-value represents results of the McNemar test.). Based on IHC 545 (98%) patients were regarded as luminal-type and the remaining 2% as Her2-type. BluePrint reclassified 2% of the clinical luminal-type patients: 4 (1%) patients were reclassified as basal-type and 3 (0%) patients as Her2-type. Of the clinical Her2-type patients 80% (n=8) was reclassified by BluePrint as molecular luminal-type. Table 2. Concordance between clinical subtyping and molecular subtyping according to BluePrint. BluePrint resultClinical SubtypeNo. ptsLuminalBasalHer2Luminal545539 (99%)4 (1%)3 (0%)Her2108 (80%)02 (20%)Note. Overall discordance 3%. Conclusion: In the current study we observe a high concordance between microarray-based assessment of ER, PR and Her2 and local pathology in Dutch ER+ early stage breast cancer patients. In the small subset of ER+ patients who are considered candidates for 70 GS use and who have HER2+ tumors by IHC molecular typing of HER2 status is of additional value. Citation Format: Kuijer A, Straver M, Elias S, Smorenburg C, Wesseling J, Linn S, Rutgers E, Siesling S, van Dalen T. Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-03-04.
- Published
- 2017
20. Screen-detected breast cancers have different tumor biology and better prognosis compared to interval breast cancers
- Author
-
Marc Schmidt, J.Lopes Cardozo, Fatima Cardoso, C. Poncet, CA Drukker, L van 't Veer, and E.J.T. Rutgers
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Screen detected ,business.industry ,Tumor biology ,Internal medicine ,Medicine ,Interval (graph theory) ,business - Published
- 2020
21. Cost-effective strategies according to the first randomized trial comparing MRI breast cancer screening with mammography in women with a familial risk: FaMRIsc
- Author
-
Amarens Geuzinge, S. Saadatmand, R.A.E.M. Tollenaar, H.J. de Koning, Ernest J. T. Luiten, Eveline A.M. Heijnsdijk, A.I.M. Obdeijn, Cees Verhoef, M.J. Hooning, E.J.T. Rutgers, Marc B Lobbes, C. Loo, Roger H. Mann, M van 't Riet, M.G.E.M. Ausems, M.M.A. Tilanus-Linthorst, J.G. Oosterwijk, D. de Roy van Zuidewijn, and Jelle Wesseling
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Familial risk ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Cancer screening ,Medicine ,Mammography ,business ,MRI breast - Published
- 2020
22. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)
- Author
-
Matador Trialists' Grp, H. van Tinteren, A.E. van Leeuwen-Stok, HM Oosterkamp, Marleen Kok, I.A.M. Mandjes, A.G.J. van Rossum, E. van Werkhoven, Monique M.E.M. Bos, Mark Opdam, Sabine C. Linn, A. van Bochove, A.L.T. Imholz, Johanneke E.A. Portielje, E.J.T. Rutgers, and Jelle Wesseling
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Cyclophosphamide ,Anthracycline ,Efficacy ,medicine.medical_treatment ,Breast Neoplasms ,Adenocarcinoma ,Taxane ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Chemotherapy ,Doxorubicin ,Progression-free survival ,Neoplasm Staging ,Netherlands ,business.industry ,Middle Aged ,medicine.disease ,Progression-Free Survival ,030104 developmental biology ,Docetaxel ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Dose-dense ,Neoplasm Recurrence, Local ,Biomarker discovery ,business ,medicine.drug - Abstract
Background Dose-dense administration of chemotherapy and the addition of taxanes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival substantially. However, clinical trials directly comparing the additive value of taxanes with dose-dense anthracycline-based chemotherapy are lacking. Patients and methods In the multicentre, randomised, biomarker discovery Microarray Analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens (MATADOR) trial, patients with pT1-3, pN0-3 breast cancer were randomised (1:1) between six adjuvant cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC) and six cycles of docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC). The primary objective was to discover a predictive gene expression profile for ddAC and TAC benefit. Here we report the preplanned secondary end-point recurrence-free survival (RFS) and overall survival (OS). Results Between 2004 and 2012, 664 patients were randomised. At 5 years, RFS was 87% (95% confidence interval [CI] 83%–91%) in the ddAC-treated patients and 88% (84–92%) in the TAC-treated subgroup (hazard ratio [HR] 0.89, 95% CI 0.62–1.28, P = 0.53). OS at 5 years was 93% (90%–96%) in the ddAC-treated and 94% (91%–97%) in the TAC-treated patients (HR 0.89, 95% CI 0.57–1.39, P = 0.61). Anaemia was more frequent in ddAC-treated patients (62/327 patients [18.9%] versus 15/319 patients [4.7%], P Conclusions With a median follow-up of 7 years, no significant differences in RFS and OS were observed between six adjuvant cycles of ddAC and TAC in high-risk breast cancer patients. Trial registration numbers ISRCTN61893718 and BOOG 2004-04.
- Published
- 2018
23. OC-0592 5 year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial
- Author
-
P. Elkhuizen, M. Vijver van der, Theodoros Foukakis, S. Vreeswijk, Sofia Rivera, H. Bartelink, D.H. Bongard van den, A.N. Scholten, F. Leij van der, E.J.T. Rutgers, and Sophie C.J. Bosma
- Subjects
Oncology ,business.industry ,Medicine ,Partial Breast Irradiation ,Radiology, Nuclear Medicine and imaging ,Hematology ,business ,Nuclear medicine - Published
- 2019
24. The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands
- Author
-
Sabine Siesling, M. van der Heiden-van der Loo, Michel W.J.M. Wouters, E.J.T. Rutgers, T. van Dalen, P. H. M. Peeters, Health Technology & Services Research, and Faculty of Behavioural, Management and Social Sciences
- Subjects
Adult ,medicine.medical_specialty ,Multivariate analysis ,Receptor, ErbB-2 ,medicine.medical_treatment ,Population ,Breast Neoplasms ,Immunoenzyme Techniques ,Breast cancer ,Biomarkers, Tumor ,Journal Article ,medicine ,Humans ,Neoplasm Invasiveness ,Registries ,IR-98991 ,education ,Survival rate ,Aged ,Neoplasm Staging ,Netherlands ,Quality Indicators, Health Care ,education.field_of_study ,Obstetrics ,business.industry ,Incidence ,Incidence (epidemiology) ,Carcinoma, Ductal, Breast ,Middle Aged ,Prognosis ,medicine.disease ,Confidence interval ,Surgery ,Cancer registry ,Survival Rate ,Carcinoma, Lobular ,Receptors, Estrogen ,Oncology ,Female ,Neoplasm Grading ,Neoplasm Recurrence, Local ,Receptors, Progesterone ,business ,METIS-314525 ,Mastectomy ,Follow-Up Studies - Abstract
Purpose: All Dutch hospitals are obliged to report their 5-year ipsilateral breast tumor recurrence (IBTR) rate after breast cancer surgery. Experts decided that these rates should not exceed 5 %. This study determined the value of IBTR as an indicator to compare quality of care between hospitals. Methods: All patients with breast cancer (pT1–3, any N, M0) who underwent surgery in 1 of 92 Dutch hospitals from 2003 to 2006 were identified in the Netherlands Cancer Registry. Data of recurrence was retrieved from hospital records. Five-year IBTR rates for breast-conserving surgery (BCS) and mastectomy were calculated by using the Kaplan–Meier method. Hospital variation was presented in funnel plots. Multivariate analysis was used to assess hospital characteristics associated with IBTR rates. Results: A total of 40,892 breast cancer patients were included. The overall 5-year IBTR rate was 2.85 % (95 % confidence interval 2.68–3.03) and was significantly lower for BCS than for mastectomy (2.38 vs. 3.45 %, p < 0.001). IBTR rates decreased over time in both groups. Rates varied between 0.77 and 5.70 % between hospitals. When random variation is taken into account, only extremely high IBTR rates can be detected as deviant from the target value of 5 %. Adjusting for tumor and patient characteristics, analyses showed that a higher volume of mastectomies is associated with lower IBTR rates. Conclusions: Our population-based findings show that IBTR rates in the Netherlands are low and have improved over time. The 5-year IBTR rate as an indicator for quality of care of individual hospitals is of limited value.
- Published
- 2015
25. Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al
- Author
-
Sara Y. Brucker, Per Karlsson, Z Shao, Monica Morrow, Bo Xu, Kathleen I. Pritchard, Meredith M. Regan, V Galimberti, Beat Thürlimann, Jonas Bergh, Michael Gnant, H.-J. Senn, Jens Huober, Zefei Jiang, Jungsil Ro, M. Toi, Giuseppe Curigliano, Toshihiro Watanabe, R Orecchia, Ian E. Smith, Hervé Bonnefoi, Daniel F. Hayes, Bahadir M. Gulluoglu, Lisa A. Carey, Prudence A. Francis, Ann H. Partridge, A. Di Leo, Giulia Viale, Timothy J. Whelan, Nadia Harbeck, Chiun-Sheng Huang, Fatima Cardoso, Judy Garber, Martine Piccart-Gebhart, Eva Ciruelos, Kent Osborne, Vladimir Semiglazov, M.A. Colleoni, Fabrice Andre, Andrew Tutt, Bent Ejlertsen, O. Pagani, S. Loibl, Carsten Denkert, H. Khaled, Jack Cuzick, Peter Dubsky, Jacek Jassem, J. Baselga, Eric P. Winer, Felix Sedlmayer, Pamela J. Goodwin, Harold J. Burstein, and E.J.T. Rutgers
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Consensus ,Receptor, ErbB-2 ,Alternative medicine ,MEDLINE ,Breast Neoplasms ,Primary therapy ,03 medical and health sciences ,0302 clinical medicine ,Radiation oncology ,medicine ,Humans ,Medical physics ,Letters to the Editor ,Early breast cancer ,Gynecology ,Point (typography) ,business.industry ,Expert consensus ,Hematology ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Radiation Oncology ,business - Published
- 2017
26. The intraoperative assessment of sentinel nodes - Standards and controversies
- Author
-
E.J.T. Rutgers, M.T.F.D. Vrancken Peeters, and M.E.M. van der Noordaa
- Subjects
medicine.medical_specialty ,Axillary lymph nodes ,medicine.medical_treatment ,Cytodiagnosis ,Breast Neoplasms ,030230 surgery ,Mastectomy, Segmental ,03 medical and health sciences ,Intraoperative Period ,0302 clinical medicine ,Breast cancer ,medicine ,Breast-conserving surgery ,Frozen Sections ,Humans ,business.industry ,Sentinel Lymph Node Biopsy ,Axillary Lymph Node Dissection ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Surgery ,Radiation therapy ,Axilla ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Lymph Node Excision ,Female ,Sentinel Lymph Node ,business ,Mastectomy - Abstract
Intraoperative assessment of sentinel lymph nodes (SLNs) has the advantage of allowing breast cancer patients with tumor-positive SLNs to avoid a second surgery by immediately proceeding to axillary lymph node dissection (ALND). However, there are several reasons why the use of intraoperative assessment should be questioned. Whereas ALND was traditionally advised for all breast cancer patients with tumor-positive lymph nodes for axillary staging and locoregional control, more recent studies have demonstrated safety of omitting ALND in a substantial number of patients. In addition, there are concerns about the accuracy of intraoperative assessment methods including frozen section analysis, touch preparation cytology and one-step nucleic acid amplification. Moreover, intraoperative assessment of SLNs denies patients the opportunity to contribute to their treatment planning. In our opinion, intraoperative assessment of axillary lymph nodes should be reserved for patients who still have a strict indication for ALND. Patients with clinical node negative disease (cN0) and one or two positive SLNs can be safely treated with breast conserving surgery and radiotherapy. There has been more controversy for cN0 patients who are treated with mastectomy since radiotherapy is not routinely administered in these patients. However, there is increasing evidence that ALND may be omitted in patients undergoing mastectomy who have a low tumor-burden in their SLNs. Therefore, we defend the position that in cN0 patients undergoing mastectomy, SLNB should be performed and full pathologic evaluation of the SLN should be awaited. In cN0 patients undergoing neoadjuvant systemic therapy (NST) intraoperative assessment of SLNs can be omitted since ALND will not provide therapeutic benefit. It is being hypothesized that patients with limited axillary disease prior to NST who remain node-positive after NST could be treated safely with axillary radiotherapy instead of ALND. In these patients, omitting intraoperative assessment might be a reasonable option. In patients with extensive nodal disease prior to NST intraoperative assessment of axillary lymph nodes should be performed.
- Published
- 2017
27. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial
- Author
-
Patrizia Dell'Orto, J. van den Akker, Giuseppe Viale, E.J.T. Rutgers, Lisette Stork-Sloots, Jan Bogaerts, L.J. van 't Veer, F de Snoo, Martine Piccart-Gebhart, Leen Slaets, Leila Russo, Fatima Cardoso, and Annuska M. Glas
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Pathology ,Microarray ,Receptor, ErbB-2 ,medicine.drug_class ,Concordance ,Statistics as Topic ,Breast Neoplasms ,Biology ,Breast cancer ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,RNA, Messenger ,skin and connective tissue diseases ,Gene ,In Situ Hybridization, Fluorescence ,Aged ,medicine.diagnostic_test ,Microarray analysis techniques ,Original Articles ,Hematology ,Middle Aged ,Microarray Analysis ,Prognosis ,medicine.disease ,Receptors, Estrogen ,Estrogen ,Protein Biosynthesis ,Immunohistochemistry ,Female ,Receptors, Progesterone ,hormones, hormone substitutes, and hormone antagonists ,Fluorescence in situ hybridization - Abstract
To investigate the correlation of TargetPrint with local and central immunohistochemistry/fluorescence in situ hybridization assessment of estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2) in the first 800 patients enrolled in the MINDACT trial.Data from local (N = 800) and central (N = 626) assessments of receptor status were collected and compared with TargetPrint results.For ER, the positive agreement (the percentage of central pathology positive assessments that were also TargetPrint/local laboratory positive) for TargetPrint in comparison to centralized assessment was 98% with a negative agreement (the percentage of central pathology negative assessments that were also TargetPrint/local laboratory negative) of 96%. For PgR, the positive agreement was 83% with a negative agreement of 92%. For HER2, the positive agreement was 75% with a negative agreement of 99%. Even though the local assessment showed higher positive agreement for PgR (89%) and higher positive agreement for HER2 (85%), the range of discordant local versus central assessments were as high as 6.7% for ER, 12.9% for PgR, and 4.3% for HER2.TargetPrint and local assessment of ER, PgR, and HER2 show high concordance with central assessment in the first 800 MINDACT patients. However, there are concerns about the higher discordance rates for some local sites. TargetPrint can improve the reliability of hormone receptor and HER2 testing for those centers with a lower rate of concordance with the reference laboratory, with the limitation of a positive agreement of 75% for HER2. TargetPrint consequently has important implications for treatment decisions in clinical practice and is a reliable alternative to local assessment for ER.NCT00433589.
- Published
- 2014
28. Mammographic screening detects low-risk tumor biology breast cancers
- Author
-
Karla Kerlikowske, E.J.T. Rutgers, Ruud M. Pijnappel, L.J. van 't Veer, Leen Slaets, Marjanka K. Schmidt, Laura J. Esserman, Fatima Cardoso, F.E. van Leeuwen, C.A. Drukker, Jan Bogaerts, and Academic Medical Center
- Subjects
Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Digital mammography ,Population ,Breast Neoplasms ,70-Gene signature ,Breast cancer ,Internal medicine ,medicine ,Humans ,Mammography ,Overdiagnosis ,education ,Early Detection of Cancer ,Aged ,Gynecology ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Tumor biology ,Film-screen mammography ,Middle Aged ,Full-field digital mammography ,medicine.disease ,Clinical Trial ,Full field digital mammography ,3. Good health ,Clinical trial ,Screening ,Female ,Transcriptome ,business - Abstract
Overdiagnosis of breast cancer, i.e. the detection of slow-growing tumors that would never have caused symptoms or death, became more prevalent with the implementation of population-based screening. Only rough estimates have been made of the proportion of patients that are overdiagnosed and identification of those patients is difficult. Therefore, the aim of this study is to evaluate whether tumor biology can help identify patients with screen-detected tumors at such a low risk of recurrence that they are likely to be overdiagnosed. Furthermore, we wish to evaluate the impact of the transition from film-screen mammography (FSM) to the more sensitive full-field digital mammography (FFDM) on the biology of the tumors detected by each screening-modality. All Dutch breast cancer patients enrolled in the MINDACT trial (EORTC-10041) accrued 2007–2011, who participated in the national screening program (biennial screening ages 50–75) were included (n = 1,165). We calculated the proportions of high-, low- and among those the ultralow-risk tumors according to the 70-gene signature for patients with screen-detected (n = 775) and interval (n = 390) cancers for FSM and FFDM. Screen-detected cancers had significantly more often a low-risk tumor biology (68 %) of which 54 % even an ultralow-risk compared to interval cancers (53 % low-, of which 45 % ultralow-risk (p = 0.001) with an OR of 2.33 (p
- Published
- 2014
29. Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature
- Author
-
A. Thompson, L.J. van 't Veer, S. Delaloge, Jan Bogaerts, Fatima Cardoso, E.J.T. Rutgers, M.J. Piccart, Isabel T. Rubio, K Aalders, C. Poncet, and Konstantinos Tryfonidis
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Breast cancer recurrence ,business.industry ,Gene signature ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Very low risk ,business - Published
- 2018
30. Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible
- Author
-
M.E.M. van der Noordaa, R. Voorthuis, M.J. Vrancken Peeters, C. Loo, J. Van Urk, E.J.T. Rutgers, I. Ioan, Vincent O. Dezentjé, E. van Werkhoven, F. van Duijnhoven, Emma J. Groen, and T. Wiersma
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Breast cancer ,business.industry ,Internal medicine ,medicine ,In patient ,medicine.disease ,business ,Systemic therapy - Published
- 2018
31. Abstract P3-03-06: Internal mammary chain sentinel nodes in early stage breast cancer patients: Towards selective removal
- Author
-
P. Elkhuizen, A. Van Loevezijn, M-Jt Vrancken Peeters, Maarten L. Donswijk, I. M. C. van der Ploeg, Sophie C.J. Bosma, Hester S. A. Oldenburg, S.A.L. Bartels, Wilma D. Heemsbergen, E.J.T. Rutgers, and F. van Duijnhoven
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Breast cancer ,Chain (algebraic topology) ,business.industry ,Internal medicine ,medicine ,Stage (cooking) ,medicine.disease ,business - Abstract
Background Internal mammary chain (IMC) sentinel nodes (SN) are visible in 1 out of 5 breast cancer patients on lymph scintigraphy after intra- or peritumoral injection of a radiopharmaceutical. The IMC SN status affects prognosis and treatment of breast cancer and IMC radiotherapy improves survival in selected patients. In contrast to the axillary SN, removal of the IMC SN is not routinely performed and often technically challenging. This study aims at determining the effect of IMC SN biopsy on recurrence-free survival (RFS) and overall survival (OS) and the identification of predictive factors for the development of IMC- and distant metastases. Methods All patients with IMC SNs were selected from a prospective database from 1999 to 2007. Following intratumoral injection of technetium-99m, conventional lymphoscintigraphy was performed. Sentinel nodes were removed in all regions with lymphatic drainage on scintigraphy. The RFS and OS were calculated for the total group and subgroups with tumor-positive, tumor-negative or non-removed IMC SN. Predictive factors were identified for tumor-positive IMC SN and for distant metastasis by regression analysis. Results Internal mammary chain SN biopsy was performed in 287 out of 336 patients (85%). The IMC SN was tumor-positive in 38 patients (13%). Patients with IMC metastasis had poorer OS compared to patients without IMC metastasis or a non-removed IMC SN (57%, 82% and 59% 10- year OS, respectively, p = 0.002). These patients also had worse RFS, mainly due to by the development of distant metastases (68%, 84% and 61% RFS, respectively, p = 0.002). Multivariable predictive for tumor-positive IMC SN were axillary metastases (PPV = 38.5%). Predictive factors for distant metastasis were tumor-positive IMC SN (HR 2.5, 95% CI; 1.0 - 5.8, p = 0.04), not removed IMC SN (HR 2.3, 95% CI; 1.0 - 5.1, P = 0.05), tumor diameter >1.5cm (HR 3.5, 95% CI; 1.6 - 8.4, p < 0.00) and age >65 years (HR 3.1, 95% CI; 1.2 - 7.7, p = 0.02, reference Conclusion Breast cancer patients with tumor-positive IMC SN have worse 10- year survival than patients with tumor-negative IMC SN, mainly due to the development of distant metastasis. The clinically relevant predictive factor for distant metastasis is tumor size >1.5cm. Radiotherapy of the IMC can improve survival. However, the cardiotoxicity of parasternal radiotherapy must be weighed against the expected survival benefit. Therefore, our current protocol is to perform IMC SN biopsy in patients younger than 70 years with a tumor diameter >1.5cm. Citation Format: van Loevezijn AA, Bartels SA, van Duijnhoven FH, Heemsbergen WD, Bosma SC, Elkhuizen PH, Donswijk ML, Rutgers EJ, Oldenburg HS, Vrancken Peeters M-JT, van der Ploeg IM. Internal mammary chain sentinel nodes in early stage breast cancer patients: Towards selective removal [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-06.
- Published
- 2019
32. Abstract P5-14-05: Preoperative accelerated partial breast irradiation (PAPBI) trial: First results on acute toxicity, complications and cosmetic results
- Author
-
D van den Bongard, Tobias Lekberg, F van der Leij, P. Elkhuizen, E.J.T. Rutgers, Harry Bartelink, and Sofia Rivera
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Wide local excision ,Cosmesis ,Sentinel node ,Ductal carcinoma ,medicine.disease ,Surgery ,Hematoma ,Oncology ,Biopsy ,medicine ,Hormonal therapy ,business - Abstract
Background The ongoing Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial (NCT01024582) was based on the rationale that three-dimensional conformal external-beam radiation (3D-CRT) leads to more dose homogeneity compared with brachy-or intraoperative radiotherapy (RT). By irradiating preoperatively this can lead to more accurate tumor delineation and smaller irradiated volumes. As the tumor remains in situ during irradiation, more precise delivery of the radiation dose is guaranteed with CT cone beam linear accelerators, avoiding the uncertainties of the original tumor position in the operation cavity as is the case in postoperative RT. Tumor excision 6 weeks after RT removes the high dose volume tissue and can lead to better cosmesis. Methods and materials Patients 60 years, T ≤ 3 cm, pN0(sn) (sentinel node procedure before RT), ductal carcinoma, unifocal on mammogram and MRI, undergo preoperative RT (CTV = GTV + 2 cm, 10 × 4 Gy IMRT/VMAT over two weeks); 6 weeks hereafter a wide local excision is performed. Skin toxicity and fibrosis is scored using EORTC/RTOG criteria. Patients are followed during RT and on a 3-monthly basis. Cosmesis is scored and photographs are taken for analysis (BCCT.core project score). Results From May 2010- 2013, 58 patients (pts) were included. For 52 pts follow up information is available up to at least 3 months after treatment; mean age 67.2 years (59-80); mean tumor size 1.4 cm (0.4-3.2); differentiation grade: grade 1 (n = 22), grade 2 (n = 28), unknown n = 8; mainly ER+PR + neu- (n = 50). 34 pts received hormonal therapy, none chemotherapy. Toxicity Acute RT toxicity grade 0 (23) grade 1(8). Postoperative complications were noted in 9/52 pts (17%): 2/52 had direct post-operative bleeding needing re-surgery; 1/52 developed a hematoma two months after surgery, needing re-surgery; 6/52 (11.5%) had a postoperative wound infection and received oral antibiotics. Of these 6; 1 wound abscess needing re-surgery; 1 small fistula closing within ten months. In the first year 9/52 pts developed localized oedema at the RT side fading away within 9 months. 4/53 pts developed hematoma post surgery. Fibrosis and cosmetic outcome Fibrosis score at 1 year (n = 35): grade 0 (9), grade 1 (21), grade 2 (4) grade 3 (1). Cosmetic outcome was scored at 1 year (n = 28): excellent/good (25; 89%), fair (3;11%). At 2 years follow up: 10/11 patients excellent/good and 1/11 patient fair. Fibrosis was noted in a limited volume. One ipsi-lateral breast tumor recurrence was diagnosed after 12 months at skin entry of the biopsy tract. Discussion The short term results of this PAPBI trial are promising in terms of acute treatment-related toxicities, complications and cosmetic outcome. Our complication rate of 17% (11% wound infection, 8% hematoma) is comparable with others*. Excellent or good cosmetic outcome was found in 90%, improving over time. Longer follow-up and increasing patient inclusion are needed to evaluate treatment efficacy, cosmetic results and toxicity on the longer term. *Mukesh et al (Eur J Surg Oncol 2012; 648 pts Cambridge IMRT trial), 18% infection, 8% hematoma. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-14-05.
- Published
- 2013
33. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
- Author
-
Gabe S. Sonke, E.J.T. Rutgers, H. van Tinteren, Jolien M. Bueno-de-Mesquita, M.J. van de Vijver, M. Knauer, W.H. van Harten, C.A. Drukker, Valesca P. Retèl, L.J. van 't Veer, Sabine C. Linn, Rudi M. H. Roumen, Jelle Wesseling, Cancer Center Amsterdam, and Pathology
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,adjuvant systemic treatment ,Adjuvant chemotherapy ,IR-86400 ,Breast Neoplasms ,Prospective evaluation ,Breast cancer ,breast cancer ,MammaPrint ,Survival probability ,Internal medicine ,medicine ,gene expression profiling ,Humans ,Prospective Studies ,Prospective cohort study ,Survival rate ,Probability ,Gynecology ,medicine.diagnostic_test ,business.industry ,Middle Aged ,medicine.disease ,Survival Rate ,Oncology ,Observational study ,METIS-296793 ,Female ,prognosis prediction ,business ,Early Detection and Diagnosis - Abstract
The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene signature, which result was available for 427 patients (cT1-3N0M0). Adjuvant systemic treatment decisions were based on the Dutch CBO 2004 guidelines, the 70-gene signature and doctors' and patients' preferences. Five-year distant-recurrence-free-interval (DRFI) probabilities were compared between subgroups based on the 70-gene signature and Adjuvant! Online (AOL) (10-year survival probability
- Published
- 2013
34. Abstract P4-11-01: Rapid genetic counseling and testing in newly diagnosed breast cancer patients, findings from an RCT
- Author
-
Marianne A. Kuenen, Arjen J. Witkamp, JJ Huisman, Johannes P. Vente, R. B. van der Luijt, Herman Rijna, J van der Sanden-Melis, B. C. Vrouenraets, T. van Dalen, Wevers, S. Verhoef, E. M. A. Bleiker, B. van Ooijen, Titia Brouwer, E. B. M. Theunissen, Neil K. Aaronson, Wim H. Bouma, M.G.E.M. Ausems, De Hahn, Heiddis Valdimarsdottir, E.J.T. Rutgers, Paul J Borgstein, Frans B. L. Hogervorst, and M.A.J. de Roos
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Genetic counseling ,Cancer ,medicine.disease ,law.invention ,Distress ,Breast cancer ,Oncology ,Quality of life ,Randomized controlled trial ,law ,Internal medicine ,Intervention (counseling) ,medicine ,Physical therapy ,business ,Psychosocial - Abstract
Introduction: Female breast cancer patients carrying a BRCA1/2 mutation have an increased risk of second primary breast and ovarian tumors. Rapid genetic counseling and testing (RGCT) may aid in making informed decisions about therapeutic and preventive surgery and adjuvant treatment. Little is known about the effects of RGCT on treatment decisions and psychosocial well-being. We have performed a randomized controlled trial to investigate these issues. Methods: Newly diagnosed breast cancer patients from 12 Dutch hospitals with at least a 10% risk of carrying a BRCA1/2 mutation were randomized to an intervention group (RGCT) or a usual care control group (ratio 2:1). Study outcomes included uptake of RGCT, choice of type of surgery, cancer risk perception, cancer-specific distress, quality of life and decisional satisfaction. Assessments took place at study entry, and at 6 and 12 months follow-up. Results: Between 2008 and 2010, 271 patients were recruited, of whom 3 subsequently withdrew. The remaining 268 patients were randomized to the intervention (n = 181) or control (n = 87) group. Complete questionnaire data were available for 250 (93%) and 243 (91%) patients at 6 and 12 months follow-up, respectively. Of the 181 women in the intervention group, 180 (98%) underwent genetic counseling after a median of 4 days. One-hundred thirteen (63%) of them opted for accelerated DNA test procedures, of whom 72 underwent rapid testing (results available in Conclusion: The uptake of rapid genetic counseling among high-risk breast cancer patients was high, and the majority of patients underwent accelerated DNA-testing procedures. However, RGCT did not have a significant effect on choice of type of primary surgery. In part, this may be explained by the fact that surgeons and patients often did not wait for DNA test results before primary surgery. Conclusions regarding the psychosocial impact of RGCT will be presented at the time of the conference. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-11-01.
- Published
- 2012
35. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy
- Author
-
M.E.M. van der Noordaa, Bas B. Koolen, M. Donker, Marieke E. Straver, E.J.T. Rutgers, R.A. Valdés Olmos, and M.T.F.D. Vrancken Peeters
- Subjects
Adult ,medicine.medical_specialty ,Axillary lymph nodes ,medicine.medical_treatment ,Breast Neoplasms ,Unnecessary Procedures ,030218 nuclear medicine & medical imaging ,Iodine Radioisotopes ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Antineoplastic Combined Chemotherapy Protocols ,Preoperative Care ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Lymph node ,Neoadjuvant therapy ,Aged ,Neoplasm Staging ,Fluorodeoxyglucose ,Postoperative Care ,business.industry ,Axillary Lymph Node Dissection ,Middle Aged ,medicine.disease ,Neoadjuvant Therapy ,Surgery ,Axilla ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Lymph Node Excision ,Female ,Lymph Nodes ,Radiopharmaceuticals ,business ,Algorithms ,medicine.drug - Abstract
Background The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND) is still the standard of care. Marking axillary lymph nodes with radioactive iodine seeds (MARI procedure) is accurate in restaging the axilla after NST (false-negative rate 7 per cent). Here, the potential of tailored axillary treatment, determined by combining the results of PET–CT before NST with those of the MARI procedure after NST, was analysed. Methods A cohort of axillary node-positive patients was used to construct a hypothetical treatment algorithm based on a combination of PET–CT and the MARI procedure. In the algorithm, the number of fluorodeoxyglucose (FDG)-avid axillary lymph nodes (1–3 versus 4 or more) before NST and the tumour status of the MARI node (positive versus negative) after NST were used to tailor axillary treatment. All patients in the cohort underwent ALND, allowing estimation of potential overtreatment and undertreatment. Results A total of 93 patients were included in the study. Between one and three FDG-avid axillary lymph nodes were observed in 59 patients, and four or more in 34 patients. The MARI node was tumour-negative in 32 patients and showed residual disease in 61. Treatment according to the constructed algorithm would have resulted in 74 per cent of patients avoiding an ALND, with potential undertreatment in three patients (3 per cent) and overtreatment in 16 (17 per cent). Conclusion Tailored axillary treatment after NST in node-positive patients, by combining PET–CT before NST and the MARI procedure after NST, has the potential for ALND to be avoided in 74 per cent of patients.
- Published
- 2016
36. Very low local recurrence rates after breast-conserving therapy : Analysis of 8485 patients treated over a 28-year period
- Author
-
E.J.T. Rutgers, M.J. van de Vijver, F. van der Leij, Sophie C.J. Bosma, Jelle Wesseling, Paula H.M. Elkhuizen, Harry Bartelink, Sabine C. Linn, E. van Werkhoven, CCA -Cancer Center Amsterdam, and Pathology
- Subjects
Adult ,medicine.medical_specialty ,Cancer Research ,Breast-conserving therapy ,Breast Neoplasms ,Segmental ,Mastectomy, Segmental ,Systemic therapy ,Tumor-free margins ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Breast cancer ,medicine ,80 and over ,Journal Article ,Combined Modality Therapy ,Chemotherapy ,Humans ,030212 general & internal medicine ,Young adult ,Survival analysis ,Adjuvant ,Mastectomy ,Aged ,Netherlands ,Aged, 80 and over ,Invasive carcinoma ,business.industry ,Age Factors ,Cancer ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Neoplasm Recurrence ,Treatment Outcome ,Local ,Oncology ,Local control ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Cohort ,Female ,Neoplasm Recurrence, Local ,business - Abstract
The purpose of this study was to study the impact of changes in clinical practice on outcome in patients treated with breast-conserving therapy (BCT) over a period of 28 years. Patients with early invasive breast cancer, who were treated with BCT at the Netherlands Cancer Institute between 1980 and 2008, were studied. Clinical characteristics, treatment and outcome were compared between groups (1980-1987; 1988-1998; 1999-2008). The main endpoint analyzed was ipsilateral breast tumor recurrence (IBTR). 8485 patients with a median follow-up of 9 years (IQR 6-14 years) were analyzed. The cumulative 5- and 10-year IBTR incidences were, respectively, 2 and 5 % for the whole cohort and 4 and 9 % in patients ≤40 years. Young age was a significant risk factor for IBTR in multivariable analysis. IBTR-free interval was better for patients who received a RT boost (HR 0.65) or systemic therapy (HR 0.52). In later years, patients less often received a boost and more often underwent adjuvant systemic treatment. 761 patients (9.0 %) underwent a re-excision; the tumor resection margins were tumor free for 85 %. In later years (1999-2008), 89 % of patients had a tumor-free margin. The margin status of invasive carcinoma did not influence IBTR, DM rate, or OS. Between 1980 and 2008, locoregional control after BCT remained stable with low IBTR rates, even in young patients. These good results were achieved under the policy of accepting close or focally positive margins, indicating this is a safe approach. The results of this study may help in lowering the re-excision rates, which are high in many centers.
- Published
- 2016
37. P1-07-06: High Concordance of Protein (by IHC), Gene (by FISH; HER-2 Only) and Microarray Readout (by TargetPrint) of ER/PR/HER2: Results from the MINDACT Trial
- Author
-
Fatima Cardoso, G. Viale, Annuska M. Glas, Patrizia Dell'Orto, Leila Russo, Jan Bogaerts, Snoo F de, E.J.T. Rutgers, Veer L van't, M.J. Piccart, and Kristel Engelen
- Subjects
Oncology ,Gynecology ,Cancer Research ,medicine.medical_specialty ,Microarray ,medicine.diagnostic_test ,business.industry ,Concordance ,Cancer ,medicine.disease ,Breast cancer ,MammaPrint ,Mrna level ,Internal medicine ,medicine ,Immunohistochemistry ,%22">Fish ,business - Abstract
Background Previously, the micro-array readout of ER, PR and HER2 by TargetPrint was shown to be strongly correlated with high quality immunohistochemistry (IHC)/FISH assessment, especially for ER and HER2. Concordance rates were 93% (k=0.79) for ER; 83% (k=0.65) for PR and 96% for HER2 (k=0.88) in 636 patients (Roepman et al., Clin Cancer Res, 2009). This study analysis was undertaken to further determine the correlation of microarray readout with IHC/FISH assessment both locally and centrally determined in the 1st 800 pts enrolled in the MINDACT trial. This work is essential to determine the quality of biological data in the two risk assessment methods used in MINDACT based upon which adjuvant chemotherapy decision is made, in order to exclude bias. Methods: ER/PR/HER2 IHC assessment was performed on the 1st 800 primary breast cancers (BC) of pts enrolled in the MINDACT study. The assessment was performed locally at each center (n=800) and by central review at the laboratory of the European Institute of Oncology (n=626). A tumor was classified positive for ER and PR when 1% of tumor cells showed positive staining. HER2 IHC status was scored as 0, 1+, 2+ or 3+; a score of 3+ was considered positive. In 2+ cases FISH was performed to assess final HER2 status. Gene expression data for ER, PR and HER2 were obtained by TargetPrint stratified as receptor positive or negative using previously determined and validated thresholds for ER, PR and HER2 mRNA levels (n=800). Results: Comparison of local assessment (IHC & FISH for HER2) with central review indicated highly similar results for receptor readout with a concordance of 98% (k=0.90) for ER; and 96% for HER2 (k=0.80) and slightly lower for PR (90% (k=0.72)). Comparison of central assessment (IHC & FISH for HER2) with micro array readout by TargetPrint indicated highly similar results for receptor readout with a concordance of 97% (k=0.88) for ER and 95% for HER2 (k=0.76). For PR the concordance was lower but still quite acceptable (85% (k=0.62)). Conclusion: Local and centrally assessed ER, PR and HER2 status in the first 800 MINDACT patient samples indicate a high level of quality for pathology in the local participating hospitals. These results exclude any bias induced by a lower quality of “traditional” pathology results as compared to the centrally assessed MammaPrint, both used for risk assessment and adjuvant chemotherapy decision in the MINDACT trial. The microarray-based assessment of ER, PR and HER2 gives results comparable to IHC & FISH and provides an objective and quantitative assessment of tumor receptor status. These results indicate that TargetPrint can serve as a second pathology assessment for locally assessed parameters, especially since TargetPrint is part of a multi-profile platform for breast cancer treatment management. This work was funded by the Breast Cancer Research Foundation and the EU Framework Program VI. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-07-06.
- Published
- 2011
38. P2-09-06: Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT during Neoadjuvant Chemotherapy
- Author
-
Peeters M-Jt Vrancken, Olmos Ra Valdés, Bas B. Koolen, K.G.A. (Kenneth) Gilhuijs, E.J.T. Rutgers, Wouter V. Vogel, Jelle Wesseling, and Kenneth E. Pengel
- Subjects
Cancer Research ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,Area under the curve ,Cancer ,Estrogen receptor ,Magnetic resonance imaging ,medicine.disease ,Primary tumor ,Breast cancer ,Oncology ,Positron emission tomography ,medicine ,Nuclear medicine ,business - Abstract
Background - Neoadjuvant chemotherapy (NAC) is increasingly applied in stage II and III breast cancer. Response monitoring with magnetic resonance imaging (MRI) has been shown valuable, but knowledge of the breast cancer subtype is essential for correct interpretation of response assessment.(Loo et al, J Clin Oncol 29:660–6, 2011) The aim of the present study was to evaluate the relevance of breast cancer subtype for 18F-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) markers for monitoring of therapy response during NAC. Methods - Evaluation included 94 women with primary stage II or III breast cancer and measurable (quantifiable) FDG tumor uptake. FDG PET/CT scans were performed before and after six weeks of NAC using similar prone patient positioning. FDG uptake of the primary tumor was quantified using maximum standardized uptake values (SUVmax). Tumors were divided into three subtypes using immunohistochemistry: human epidermal growth factor receptor 2 (HER2) positive, estrogen receptor (ER) positive/HER2 negative and triple negative. Tumor response was assessed as presence of residual tumor in the surgery specimen (no response or partial response) or absence thereof (near complete or complete response). Multivariate regression analysis and receiver operating characteristic (ROC) analyses were employed to determine significant associations. Results - A (near) complete response at pathology was observed in 16 (73%) of 22 HER2 positive tumors, 5 (12%) of 43 ER positive/HER2 negative tumors and 20 (69%) of 29 triple negative tumors. In the multivariate regression analysis for the whole group, (near) complete response in the surgery specimen was significantly associated with relative reduction of SUVmax of the tumor between both scans and breast cancer subtype (area under the curve of the ROC curve 0.88 [95% confidence interval 0.81−0.95], p Conclusion - Knowledge of the breast cancer subtype appears relevant for the assessment of response to NAC with FDG PET/CT. Response monitoring with FDG PET/CT may predict a pathological response adequately in ER positive/HER2 negative and triple negative tumors, but seems less accurate in HER2 positive tumors. The reasons for these differences need to be elucidated in further investigations. Disclosure - This study was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project Breast CARE (grant 030–104). Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-09-06.
- Published
- 2011
39. PO-070 Identification of risk factors for subsequent invasive breast cancer after primary DCIS by transcriptomic profiling
- Author
-
Marc Schmidt, Lotte E. Elshof, Michael Schaapveld, Lindy L. Visser, F.E. van Leeuwen, Esther H. Lips, Marlous Hoogstraat, Jelle Wesseling, and E.J.T. Rutgers
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Population ,Ductal carcinoma ,medicine.disease ,body regions ,Transcriptome ,Lesion ,Breast cancer screening ,Breast cancer ,Internal medicine ,Cohort ,Breast-conserving surgery ,medicine ,medicine.symptom ,skin and connective tissue diseases ,business ,education ,neoplasms - Abstract
Introduction Ductal carcinoma in situ (DCIS) is a pre-invasive breast lesion, frequently detected by breast cancer screening, with thousands of new cases each year. While DCIS is not life threatening, it does increase a women’s risk of developing invasive breast cancer; this in turn can lead to breast-cancer specific mortality. Therefore, almost all DCIS lesions are treated to prevent progression to invasive disease. However, many DCIS lesion will never develop into invasive breast cancer if left untreated, indicating that many women are overtreated. In this study, we performed RNA sequencing (RNAseq) on a large set of primary DCIS lesions, comparing lesions with a subsequent invasive breast cancer recurrence (IBCR) to those without, to identify factors distinguishing harmless from potentially hazardous DCIS. Material and methods We made use of a DCIS case-control series, nested in a nation-wide population-based cohort of Dutch women diagnosed with primary DCIS and treated with breast conserving surgery alone (standard clinical practice) between 1989–2005. Mean follow up time was 12.0 years. RNA was extracted from FFPE laser-microdissected tissue fragments of 183 primary DCIS lesions: 100 associated with subsequent IBCR and 83 which remained free of invasive recurrence. RNAseq was performed to identify differentially expressed genes between DCIS with and without IBCR. Subsequently, gene set enrichment analysis (GSEA) was performed. Finally, findings were correlated with patients’ clinical and histopathological characteristics. Results and discussions DCIS lesions were categorised into PAM50 intrinsic subtypes: Luminal A 25%, Luminal B 38%, Her2 22%, Basal 10%, Normal 5%. Within each PAM50 subtype, 1 to 64 genes were statistically significant (p Conclusion To our knowledge, we performed the first large-scale transcriptome analysis of primary DCIS lesions with and without subsequent IBCR and long-term follow-up. Our data suggest that immune-related pathways are involved in DCIS progression. The results of our study add to the current understanding of DCIS and to risk stratification of DCIS in the near future.
- Published
- 2018
40. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing
- Author
-
Senno Verhoef, E. van Riel, E.J.T. Rutgers, Margreet G. E. M. Ausems, C C Wárlám-Rodenhuis, and Human Genetics
- Subjects
Adult ,Male ,Health Knowledge, Attitudes, Practice ,medicine.medical_specialty ,Referral ,Attitude of Health Personnel ,Genetic counseling ,Genes, BRCA2 ,Genes, BRCA1 ,Breast Neoplasms ,Genetic Counseling ,Breast cancer ,Surveys and Questionnaires ,Adjuvant therapy ,medicine ,Humans ,Genetic Testing ,Practice Patterns, Physicians' ,Referral and Consultation ,Aged ,Netherlands ,Genetic testing ,Response rate (survey) ,medicine.diagnostic_test ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Distress ,Oncology ,Family medicine ,Female ,business - Abstract
This study explores knowledge about hereditary breast cancer, attitudes about BRCA testing and referral pattern to a family cancer clinic among medical specialists. A total of 92 questionnaires were completed by surgeons (38), medical oncologists (29), radiation oncologists (13) and radiologists (12). The response rate was 51%. A substantial (11-56%) proportion of medical specialists do not refer patients who meet current criteria for BRCA testing. Although questions on inheritance were less well answered, overall knowledge was good. They had a positive attitude, but were concerned about the distress DNA testing might cause to family members. The majority (75%) stated that the best time for referral is after adjuvant therapy or during follow-up, but another important determinant was the patient's wish or need (12%). Further studies are needed to gain insight into the actual referral process, while ongoing training of medical specialists about genetic aspects of breast cancer is also necessary.
- Published
- 2010
41. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer
- Author
-
Marieke E. Straver, Tanja Alderliesten, Claudette E. Loo, M.T.F.D. Vrancken Peeters, E.J.T. Rutgers, and Other departments
- Subjects
Adult ,medicine.medical_specialty ,Axillary lymph nodes ,medicine.medical_treatment ,Biopsy, Fine-Needle ,Breast Neoplasms ,Iodine Radioisotopes ,Breast cancer ,medicine ,Breast-conserving surgery ,Humans ,Radionuclide Imaging ,Lymph node ,Ultrasonography, Interventional ,Aged ,business.industry ,Axillary Lymph Node Dissection ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Surgery ,Axilla ,medicine.anatomical_structure ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Feasibility Studies ,Lymph Node Excision ,Female ,Lymph Nodes ,Lymph ,Radiopharmaceuticals ,business - Abstract
Background An important benefit of neoadjuvant chemotherapy is the increased potential for breast-conserving surgery. At present the response of axillary lymph node metastases to chemotherapy is not easily assessed, rendering axilla-conserving treatment difficult. The aim was to assess a new surgical method for evaluating the axillary response to chemotherapy. Methods Before neoadjuvant chemotherapy, proven tumour-positive axillary lymph nodes were localized using ultrasound-guided insertion of iodine-125-labelled (I-125) seeds. After neoadjuvant chemotherapy, the marked lymph nodes were removed selectively with the use of a γ probe. A complete axillary lymph node clearance was carried out to determine whether the pathological response in the marked node was indicative of that in the other lymph nodes. Results Tumour-positive axillary lymph nodes were localized successfully with I-125 seeds in 15 patients. The marked lymph node was detected and removed selectively after neoadjuvant chemotherapy in all patients. The pathological response to chemotherapy in the marked lymph node was indicative of the overall response in other removed lymph nodes. Conclusion This study showed that marking and selectively removing metastatic lymph nodes after neoadjuvant chemotherapy was feasible. The tumour response in the marked lymph node may be used to tailor further axillary treatment, making axilla-conserving surgery a possibility.
- Published
- 2010
42. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
- Author
-
L.J. van 't Veer, M.J. van de Vijver, E.J.T. Rutgers, I. Eekhout, Marc Schmidt, Annuska M. Glas, Britta Weigelt, Bas Kreike, Arno Floore, S. Mook, Other departments, Cancer Center Amsterdam, and Pathology
- Subjects
Oncology ,medicine.medical_specialty ,Time Factors ,Breast Neoplasms ,Metastasis ,Breast cancer ,MammaPrint ,Internal medicine ,Medicine ,Humans ,Neoplasm Metastasis ,Early Detection of Cancer ,Aged ,Neoplasm Staging ,Gynecology ,medicine.diagnostic_test ,business.industry ,Gene Expression Profiling ,Hazard ratio ,Carcinoma ,Cancer ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Chemotherapy regimen ,Survival Analysis ,Gene Expression Regulation, Neoplastic ,Tissue Array Analysis ,Hormonal therapy ,Female ,Breast disease ,business - Abstract
Background The majority of breast cancer patients are postmenopausal women who are increasingly being offered adjuvant chemotherapy. Since the beneficial effect of chemotherapy in postmenopausal patients predominantly occurs in the first 5 years after diagnosis, a prognostic marker for early events can be of use for adjuvant treatment decision making. The aim of this study was to evaluate the prognostic value of the 70-gene prognosis signature for early events in postmenopausal patients. Methods Frozen tumor samples from 148 patients aged 55–70 years were selected (T1–2, N0) and classified by the 70-gene prognosis signature (MammaPrint™) into good or poor prognosis. Eighteen percent received hormonal therapy. Results Breast cancer-specific survival (BCSS) at 5 years was 99% for the good-prognosis signature versus 80% for the poor-prognosis signature group (P = 0.036). The 70-gene prognosis signature was a significant and independent predictor of BCCS during the first 5 years of follow-up with an adjusted hazard ratio of 14.4 (95% confidence interval 1.7–122.2; P = 0.01) at 5 years. Conclusion The 70-gene prognosis signature can accurately select postmenopausal patients at low risk of breast cancer-related death within 5 years of diagnosis and can be of clinical use in selecting postmenopausal women for adjuvant chemotherapy.
- Published
- 2010
43. Gene expression profiling in breast cancer – design of a pooled database to address open questions
- Author
-
E.J.T. Rutgers, Sabine C. Linn, E. Wenzl, L.J. van 't Veer, and M. Knauer
- Subjects
Database ,Whole genome microarray ,business.industry ,Microarray analysis techniques ,medicine.medical_treatment ,computer.software_genre ,medicine.disease ,Gene expression profiling ,Breast cancer ,medicine ,Surgery ,In patient ,DNA microarray ,business ,Adjuvant ,computer ,Pathological - Abstract
BACKGROUND: The Netherlands Cancer Institute used DNA microarray analyses to identify a 70-gene expression profile strongly predictive of a short interval to distant metastases in breast cancer. For patients with small tumors, the signature is not yet adequately validated. Furthermore, 95% of estrogen-receptor or triple-negative tumors are assigned to poor prognosis by the profile. METHODS: A pooled database was constructed containing clinical, pathological and microarray data of 1696 patients. The database will be used to study the performance of the 70-gene profile in patients with small-sized T1 tumors. In addition, patients with triple-negative tumors will be identified and whole genome microarray analysis will be performed of these tumors to develop a new prognostic gene expression profile for this subgroup. RESULTS AND CONCLUSIONS: If the 70-gene profile is accurate for small tumors, patients at risk may be assigned to adjuvant treatment. A new prognostic classifier for triple-negative tumors may help to identify women, in whom adjuvant treatment may safely be omitted.
- Published
- 2009
44. Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: Lasting local control and acceptable morbidity
- Author
-
Jelle Wesseling, E.J.T. Rutgers, Tjeerd S. Aukema, and Nicola S. Russell
- Subjects
Adult ,medicine.medical_specialty ,Mammaplasty ,Breast Neoplasms ,Autologous tissue ,Transplantation, Autologous ,Surgical Flaps ,Resection ,Postoperative Complications ,Breast cancer ,medicine ,Humans ,First Recurrence ,Recurrent breast cancer ,Aged ,Aged, 80 and over ,business.industry ,Soft tissue ,General Medicine ,Split skin graft ,Middle Aged ,Greater omentum ,medicine.disease ,Surgery ,Survival Rate ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Introduction Locoregional breast cancer recurrence can be detected at an advanced stage of the disease. To achieve local control for these larger local breast cancer recurrences, wide soft tissue resections with autologous tissue coverage of the defect is an option. The aim of this study was to assess the local control and morbidity of surgical salvage of patients with advanced local breast cancer recurrence using autologous tissue closure of the defect. Material and methods Eighty-eight patients were treated with wide soft tissue resections with autologous tissue coverage from 1993 to 2006. Two different operating techniques were used for closure of the defect; transposition of the greater omentum covered with split skin graft and the latissimus dorsi musculo-cutaneous flap. Demographic, treatment and mortality information were retrieved from original patients' files. Results Postoperatively 10 patients (11%) developed complications which required an additional operation. In patients treated with curative intent ( n =67) median disease-free interval after extensive surgery was 24 months and median survival was 45 months. In 42 patients (47% of all included patients) the first recurrence after extensive surgery was a locoregional relapse. The two surgical techniques did not differ in overall survival ( p =0.739) and local control. Conclusion Large soft tissue resection for extensive local relapse of breast cancer may result in lasting local control in half of the patients with acceptable morbidity.
- Published
- 2009
45. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients
- Author
-
J.W.R. Nortier, E. Meershoek-Klein Kranenbarg, E.J.T. Rutgers, D.B.Y. Fontein, P J Marang-van de Mheen, Melissa Kool, C.J.H. van de Velde, and Other departments
- Subjects
Oncology ,Adult ,Endocrine therapy ,Quality of life ,medicine.medical_specialty ,Time Factors ,Antineoplastic Agents, Hormonal ,medicine.medical_treatment ,Population ,Extended adjuvant therapy ,Breast Neoplasms ,Disease-Free Survival ,Breast cancer ,Internal medicine ,Surveys and Questionnaires ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Prospective Studies ,Stage (cooking) ,Adverse effect ,education ,Aged ,Neoplasm Staging ,education.field_of_study ,business.industry ,Standard treatment ,General Medicine ,Middle Aged ,medicine.disease ,humanities ,Postmenopause ,Treatment Outcome ,Chemotherapy, Adjuvant ,Physical therapy ,Surgery ,Female ,business ,Adjuvant - Abstract
Objectives: The standard treatment for hormone-receptor positive, postmenopausal early breast cancer patients is 5 years of adjuvant endocrine therapy. Previous studies demonstrate that prolonging adjuvant endocrine therapy may improve disease-free survival. However, endocrine therapy is known for its adverse events, which may negatively affect Quality of Life (QoL). The aim of this study is to assess the impact of extended adjuvant endocrine therapy on long-term QoL outcomes. Methods: 471 patients selected from the IDEAL trial were invited to complete a questionnaire 1-1.5 years after starting with extended therapy. The questionnaire consisted of the EORTC QLQ-C30 and QLQ-BR23 questionnaires. Mean QoL outcomes were compared with EORTC reference values for stage I and II breast cancer patients and the general population. Furthermore, QoL outcomes were compared between different treatment regimens. A difference of eight points was considered clinically relevant. Results: IDEAL patients receiving extended adjuvant endocrine therapy have significantly and clinically relevant better global QoL compared with reference values for stage I and II breast cancer patients (79.6 versus 64.6; p
- Published
- 2015
46. Optimal breast cancer pathology manifesto
- Author
-
Giuseppe Viale, E.J.T. Rutgers, Tibor Tot, E. Bergsten-Nordström, and Ana Costa
- Subjects
Manifesto ,Cancer Research ,Pathology ,medicine.medical_specialty ,Biopsy ,Breast Neoplasms ,Breast pathology ,Workflow ,Breast cancer ,Predictive Value of Tests ,medicine ,Humans ,Cooperative Behavior ,Quality Indicators, Health Care ,Service (business) ,Pathology, Clinical ,business.industry ,Cancer ,Reproducibility of Results ,Guideline ,medicine.disease ,Oncology ,Job Description ,Models, Organizational ,Female ,Interdisciplinary Communication ,business - Abstract
This manifesto was prepared by a European Breast Cancer (EBC) Council working group and launched at the European Breast Cancer Conference in Glasgow on 20 March 2014. It sets out optimal technical and organisational requirements for a breast cancer pathology service, in the light of concerns about variability and lack of patient-centred focus. It is not a guideline about how pathology services should be performed. It is a call for all in the cancer community – pathologists, oncologists, patient advocates, health administrators and policymakers – to check that services are available that serve the needs of patients in a high quality, timely way.
- Published
- 2015
47. Cost-Effectiveness of 18f-Fdg Pet/Ct for Screening Distant Metastasis in Stage Ii/Iii Breast Cancer Patients of the UK, the United States and the Netherlands
- Author
-
R.A. Valdés Olmos, Anna Miquel-Cases, E.J.T. Rutgers, Suzana C Teixeira, van W.H. Harten, Lotte Maria Gertruda Steuten, Valesca P. Retèl, and Faculty of Behavioural, Management and Social Sciences
- Subjects
Oncology ,Gynecology ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Cost effectiveness ,Health Policy ,medicine.medical_treatment ,Public Health, Environmental and Occupational Health ,Distant metastasis ,Cancer ,Stage ii ,medicine.disease ,Breast cancer ,Internal medicine ,Epidemiology ,medicine ,Fdg pet ct ,business - Abstract
Objectives: 18F-FDG-PET/CT is accurate in detecting distant metastases (DM) in breast cancer patients scheduled for neoadjuvant chemotherapy. If DMs are screen-detected in an early phase, morbidity and mortality may be reduced. Because 18F-FDG-PET/CT comes at a significant cost, we compared its expected cost-effectiveness in stage II/III breast cancer patients of the UK, the US and the Netherlands (NL) vs. the gold-standard (X-thorax/liver sonography/bone scan (UK/NL) and CT-thorax-abdomen/bone scan (US)). Methods: A time-dependent Markov model compared expected Life Year (LY) and cost/Quality-adjusted Life Year (QALY) gained in four breast cancer subtypes (ER-/HER2+;ER+/HER2+;ER-/HER2-;ER+/HER2-) over a 5-year time horizon from a hospital perspective. Sensitivity and specificity of imaging and type of systemic and local treatments were derived from the Netherlands Cancer Institute. Epidemiological, survival and utility data were estimated from literature or informed by expert assumptions. Costs (2013) were derived from national tariffs (UK and NL), and from the Centres for Medicaid and Medicare Services (US). Results: 18F-FDG-PET/CT is more sensitive (53% vs. 15%) and specific (97% vs. 94%) than the gold-standard. LYs and QALYs gained were similar across subtypes, ranging from 0.025 to 0.027 and 0.0037 to 0.0044 respectively. In all countries, ER+HER2+ was the least and ER+HER2- the most costly group. 18F-FDG-PET/CT is expected to be cost-effective in the NL and the US (with highest ICERs of €165/QALY in ER+/HER2+ and $750 in ER-HER2+), with probabilities of cost-effectiveness ranging from 46-52% and 62-72% respectively, but not in the UK, with a 66-75% probability, depending on tumor subtype. Conclusions: Using 18F-FDG-PET/CT for DM screening in stage II/III breast cancer is expected to result in incremental QALY gains in all subtypes and countries. Due to costs differences between countries, 18F-FDG-PET/CT is expected to be cost-effective in the US and the NL, but not in the UK.
- Published
- 2015
48. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer
- Author
-
Nicoline Hoogerbrugge, Sybren L. Meijer, H.J. de Koning, Jan C. Oosterwijk, Theo Kok, Carla Boetes, H. M. Zonderland, A. P. E. Besnard, Caroline Seynaeve, Inge Marie Obdeijn, R. A. Manoliu, Mieke Kriege, Hans Peterse, Madeleine M. A. Tilanus-Linthorst, Sara H. Muller, E.J.T. Rutgers, C.C.M. Bartels, J.G.M. Klijn, C.T.M. Brekelmans, Rob A. E. M. Tollenaar, Radiology and Nuclear Medicine, Pathology, Medical Oncology, Radiology & Nuclear Medicine, Surgery, Internal Medicine, Public Health, Faculteit Medische Wetenschappen/UMCG, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Targeted Gynaecologic Oncology (TARGON)
- Subjects
Cancer Research ,Pathology ,Genetics and epigenetic pathways of disease [NCMLS 6] ,SURGERY ,HIGH FAMILIAL RISK ,tumorcharacteristics ,Epidemiology ,Mass Screening ,MR MAMMOGRAPHY ,ULTRASOUND ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,inherited risk ,medicine.diagnostic_test ,WOMEN ,Magnetic Resonance Imaging ,Oncology ,Invasive lobular carcinoma ,Female ,Radiology ,MRI ,medicine.medical_specialty ,Tumor suppressor gene ,mammography ,Early detection ,Breast Neoplasms ,MUTATION CARRIERS ,DIAGNOSIS ,Sensitivity and Specificity ,INVASIVE LOBULAR CARCINOMA ,Molecular epidemiology [NCEBP 1] ,breast cancer ,Breast cancer ,SDG 3 - Good Health and Well-being ,Translational research [ONCOL 3] ,SURVEILLANCE ,medicine ,Humans ,Mammography ,Genetic Predisposition to Disease ,Risk factor ,Hereditary cancer and cancer-related syndromes [ONCOL 1] ,business.industry ,screening ,MAMMOGRAPHIC FINDINGS ,Histology ,BRCA1 ,medicine.disease ,BRCA2 ,Early Diagnosis ,business - Abstract
In the MRISC study, women with an inherited risk for breast cancer were screened by a 6-month clinical breast examination (CBE) and yearly MRI and mammography. We found that the MRISC screening scheme could facilitate early breast cancer diagnosis and that MRI was a more sensitive screening method than mammography, but less specific. In the current study we investigated the contribution of MRI in the early detection of breast cancer in relation to␣tumor characteristics. From November 1999 to October 2003, 1909 women were included and 50 breast cancers were detected, of which 45 were evaluable and included in the current study. We compared the characteristics of tumors detected by MRI-only with those of all other (non-palpable) screen-detected tumors. Further, we compared the sensitivity of mammography and MRI within subgroups according to different tumor characteristics. Twenty-two (49%) of the 45 breast cancers were detected by MRI and not visible at mammography, of which 20 (44%) were also not palpable (MRI-only detected tumors). MRI-only detected tumors were more often node-negative than other screen-detected cancers (94 vs. 59%; P = 0.02) and tended to be more often ≤1 cm (58 vs. 31%; P = 0.11). MRI was more sensitive than mammography for a wide spectrum of invasive tumor characteristics i.e., size, nodal status, histology, grade and ER status. Half of the breast cancers detected in this study were visible by MRI only and these tumors were smaller and significantly more often node-negative than other screen-detected tumors, suggesting that MRI makes an important contribution to the early detection of hereditary breast cancer.
- Published
- 2006
49. Early detection of breast and ovarian cancer in families with BRCA mutations
- Author
-
Jan C. Oosterwijk, E.J.T. Rutgers, Louk V.A.M. Beex, H. Boonstra, Hans F. A. Vasen, E. Tesfay, R. Verheyen, Marian J.E. Mourits, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Targeted Gynaecologic Oncology (TARGON)
- Subjects
Oncology ,Cancer Research ,endocrine system diseases ,medicine.medical_treatment ,Genes, BRCA2 ,BRCA ,Genes, BRCA1 ,Cohort Studies ,Risk Factors ,HISTORY ,Prospective Studies ,skin and connective tissue diseases ,Lymph node ,Molecular diagnosis, prognosis and monitoring [UMCN 1.2] ,Ovarian Neoplasms ,RISK ,medicine.diagnostic_test ,PROPHYLACTIC MASTECTOMY ,WOMEN ,Middle Aged ,CARRIERS ,female genital diseases and pregnancy complications ,Pedigree ,ovarian cancer ,medicine.anatomical_structure ,OOPHORECTOMY ,Female ,Adult ,medicine.medical_specialty ,Breast Neoplasms ,MAMMOGRAPHY ,breast cancer ,Breast cancer ,Internal medicine ,SURVEILLANCE ,medicine ,Humans ,Mammography ,Aged ,Gynecology ,business.industry ,BRCA mutation ,Oophorectomy ,Cancer ,Immunotherapy, gene therapy and transplantation [UMCN 1.4] ,Prophylactic Mastectomy ,EFFICACY ,medicine.disease ,GENE ,Early Diagnosis ,CA-125 Antigen ,Mutation ,business ,Ovarian cancer - Abstract
Contains fulltext : 48740.pdf (Publisher’s version ) (Closed access) Women at risk of breast and ovarian cancer due to a genetic predisposition may opt for preventive surgery or surveillance. The aim of this study was to determine the effectiveness of surveillance in families with a BRCA mutation. Sixty-eight BRCA-families underwent surveillance using annual mammography, transvaginal ultrasound, and estimation of CA125. Two hundred and two women had at least one breast examination, and 138 at least one examination of the ovaries. After a mean follow-up of 33 months, breast cancer was detected in 21 women, four with lymph node metastases. After a mean follow-up of 37 months, six advanced ovarian cancers were detected. The percentage of metastatic breast cancers in the current study appeared to be acceptable. However, because these women have a high-risk of developing breast cancer, they still have a substantial risk of developing metastatic disease under surveillance. Surveillance for ovarian cancer was not effective.
- Published
- 2005
50. Predictors of patients’ choices for breast-conserving therapy or mastectomy: a prospective study
- Author
-
M. A. G. Sprangers, E.J.T. Rutgers, Jan Mulder, Ernest J. T. Luiten, Frans Oort, Sjaak Molenaar, H de Haes, Patient Care Support, Medical Psychology, APH - Amsterdam Public Health, and CCA -Cancer Center Amsterdam
- Subjects
Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Cross-sectional study ,medicine.medical_treatment ,Decision Making ,Breast Neoplasms ,Mastectomy, Segmental ,Decision Support Techniques ,Clinical ,Breast cancer ,Patient satisfaction ,breast cancer ,Quality of life ,Risk Factors ,medicine ,Decision aids ,Humans ,Prospective cohort study ,Mastectomy ,Aged ,Demography ,Aged, 80 and over ,treatment decision making ,Physician-Patient Relations ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Cross-Sectional Studies ,Oncology ,Social Class ,decision aids ,Patient Satisfaction ,Family medicine ,Quality of Life ,Female ,business ,Forecasting - Abstract
A study was undertaken to describe the treatment preferences and choices of patients with breast cancer, and to identify predictors of undergoing breast-conserving therapy (BCT) or mastectomy (MT). Consecutive patients with stage I/II breast cancer were eligible. Information about predictor variables, including socio-demographics, quality of life, patients' concerns, decision style, decisional conflict and perceived preference of the surgeon was collected at baseline, before decision making and surgery. Patients received standard information (n = 88) or a decision aid (n = 92) as a supplement to support decision making. A total of 180 patients participated in the study. In all, 72% decided to have BCT (n = 123); 28% chose MT (n = 49). Multivariate analysis showed that what patients perceived to be their surgeons' preference and the patients' concerns regarding breast loss and local tumour recurrence were the strongest predictors of treatment preference. Treatment preferences in itself were highly predictive of the treatment decision. The decision aid did riot influence treatment choice. The results of this study demonstrate that patients' concerns and their perceptions of the treatment preferences of the physicians are important factors in patients' decision making. Adequate information and communication are essential to base treatment decisions on realistic concerns, and the treatment preferences of patients, (C) 2004 Cancer Research UK
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.